
Gerhard Rogler

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3225626/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis. Journal of Crohn's and Colitis, 2010, 4, 7-27.	0.6	1,050
2	Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion Journal of Clinical Investigation, 1996, 97, 1715-1722.	3.9	721
3	Nuclear factor κB is activated in macrophages and epithelial cells of inflamed intestinal mucosa. Gastroenterology, 1998, 115, 357-369.	0.6	661
4	Extraintestinal Manifestations of Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2015, 21, 1982-1992.	0.9	565
5	Vagus Nerve as Modulator of the Brain–Gut Axis in Psychiatric and Inflammatory Disorders. Frontiers in Psychiatry, 2018, 9, 44.	1.3	564
6	3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 2: Surgical Management and Special Situations. Journal of Crohn's and Colitis, 2017, 11, 135-149.	0.6	558
7	Imaging techniques for assessment of inflammatory bowel disease: Joint ECCO and ESGAR evidence-based consensus guidelines. Journal of Crohn's and Colitis, 2013, 7, 556-585.	0.6	541
8	Cytokines in Inflammatory Bowel Disease. World Journal of Surgery, 1998, 22, 382-389.	0.8	447
9	Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 3: Special situations. Journal of Crohn's and Colitis, 2013, 7, 1-33.	0.6	422
10	Frequency and Risk Factors for Extraintestinal Manifestations in the Swiss Inflammatory Bowel Disease Cohort. American Journal of Gastroenterology, 2011, 106, 110-119.	0.2	410
11	Probiotic Escherichia coli Nissle 1917 Inhibits Leaky Gut by Enhancing Mucosal Integrity. PLoS ONE, 2007, 2, e1308.	1.1	386
12	Memory B Cells Activate Brain-Homing, Autoreactive CD4+ T Cells in Multiple Sclerosis. Cell, 2018, 175, 85-100.e23.	13.5	350
13	European Evidence-based Consensus: Inflammatory Bowel Disease and Malignancies. Journal of Crohn's and Colitis, 2015, 9, 945-965.	0.6	328
14	Mechanisms, Management, and Treatment of Fibrosis in Patients With Inflammatory Bowel Diseases. Gastroenterology, 2017, 152, 340-350.e6.	0.6	317
15	Smoking Cessation Induces Profound Changes in the Composition of the Intestinal Microbiota in Humans. PLoS ONE, 2013, 8, e59260.	1.1	305
16	lron deficiency across chronic inflammatory conditions: International expert opinion on definition, diagnosis, and management. American Journal of Hematology, 2017, 92, 1068-1078.	2.0	290
17	Chronic ulcerative colitis and colorectal cancer. Cancer Letters, 2014, 345, 235-241.	3.2	280
18	Microbial network disturbances in relapsing refractory Crohn's disease. Nature Medicine, 2019, 25, 323-336.	15.2	277

#	Article	IF	CITATIONS
19	Extraintestinal Manifestations of Inflammatory Bowel Disease: Current Concepts, Treatment, and Implications for Disease Management. Gastroenterology, 2021, 161, 1118-1132.	0.6	267
20	Both donor and recipient NOD2/CARD15 mutations associate with transplant-related mortality and GvHD following allogeneic stem cell transplantation. Blood, 2004, 104, 889-894.	0.6	266
21	Wound healing and fibrosis in intestinal disease. Gut, 2007, 56, 130-139.	6.1	262
22	Symptoms of Depression and Anxiety Are Independently Associated With Clinical Recurrence of Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, 2016, 14, 829-835.e1.	2.4	260
23	Interleukin-10 Blocked Endoplasmic Reticulum Stress in Intestinal Epithelial Cells: Impact on Chronic Inflammation. Gastroenterology, 2007, 132, 190-207.	0.6	255
24	Hypoxia ameliorates intestinal inflammation through NLRP3/mTOR downregulation and autophagy activation. Nature Communications, 2017, 8, 98.	5.8	224
25	Titanium dioxide nanoparticles exacerbate DSS-induced colitis: role of the NLRP3 inflammasome. Gut, 2017, 66, 1216-1224.	6.1	223
26	Deviations in human gut microbiota: a novel diagnostic test for determining dysbiosis in patients with IBS or IBD. Alimentary Pharmacology and Therapeutics, 2015, 42, 71-83.	1.9	218
27	Use of Self-Expandable Plastic Stents For the Treatment of Esophageal Perforations and Symptomatic Anastomotic Leaks. Endoscopy, 2004, 36, 695-699.	1.0	204
28	Systematic evaluation of risk factors for diagnostic delay in inflammatory bowel disease. Inflammatory Bowel Diseases, 2012, 18, 496-505.	0.9	204
29	Growth of Epithelial Organoids in a Defined Hydrogel. Advanced Materials, 2018, 30, e1801621.	11.1	200
30	Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial. Lancet, The, 2021, 397, 2372-2384.	6.3	194
31	Diagnostic Delay in Crohn's Disease Is Associated With a Complicated Disease Course and Increased Operation Rate. American Journal of Gastroenterology, 2013, 108, 1744-1753.	0.2	175
32	Chronological Order of Appearance of Extraintestinal Manifestations Relative to the Time of IBD Diagnosis in the Swiss Inflammatory Bowel Disease Cohort. Inflammatory Bowel Diseases, 2015, 21, 1794-1800.	0.9	175
33	NLRP3 tyrosine phosphorylation is controlled by protein tyrosine phosphatase PTPN22. Journal of Clinical Investigation, 2016, 126, 1783-1800.	3.9	171
34	Abdominal MRI after enteroclysis or with oral contrast in patients with suspected or proven Crohn's disease. Clinical Gastroenterology and Hepatology, 2004, 2, 491-497.	2.4	170
35	Prognostic significance of NOD2/CARD15 variants in HLA-identical sibling hematopoietic stem cell transplantation: effect on long-term outcome is confirmed in 2 independent cohorts and may be modulated by the type of gastrointestinal decontamination. Blood, 2006, 107, 4189-4193.	0.6	170
36	Comparison of capsule endoscopy and magnetic resonance (MR) enteroclysis in suspected small bowel disease. International Journal of Colorectal Disease, 2006, 21, 97-104.	1.0	167

#	Article	IF	CITATIONS
37	Isolation and phenotypic characterization of colonic macrophages. Clinical and Experimental Immunology, 1998, 112, 205-215.	1.1	164
38	Dietary Guidance From the International Organization for the Study of Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology, 2020, 18, 1381-1392.	2.4	161
39	The intestinal microbiota: its role in health and disease. European Journal of Pediatrics, 2015, 174, 151-167.	1.3	144
40	Smoking Cessation Alters Intestinal Microbiota. Inflammatory Bowel Diseases, 2014, 20, 1496-1501.	0.9	142
41	<i>In vivo</i> treatment with the herbal phenylethanoid acteoside ameliorates intestinal inflammation in dextran sulphate sodium-induced colitis. Clinical and Experimental Immunology, 2007, 148, 373-381.	1.1	141
42	Autologous Hematopoetic Stem Cell Transplantation for Refractory Crohn Disease. JAMA - Journal of the American Medical Association, 2015, 314, 2524.	3.8	136
43	Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn's disease (ANDANTE I and II). Gut, 2019, 68, 40-48.	6.1	132
44	Results of the 4th scientific workshop of the ECCO (I): Pathophysiology of intestinal fibrosis in IBD. Journal of Crohn's and Colitis, 2014, 8, 1147-1165.	0.6	131
45	Circulating levels of chemerin and adiponectin are higher in ulcerative colitis and chemerin is elevated in Crohn's disease. Inflammatory Bowel Diseases, 2010, 16, 630-637.	0.9	129
46	Cell-Cell Contacts Prevent Anoikis in Primary Human Colonic Epithelial Cells. Gastroenterology, 2007, 132, 587-600.	0.6	127
47	Deep Remission at 1 Year Prevents Progression of Early Crohn's Disease. Gastroenterology, 2020, 159, 139-147.	0.6	126
48	Gastrointestinal and liver adverse effects of drugs used forÂtreating IBD. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2010, 24, 157-165.	1.0	124
49	The heart and the gut. European Heart Journal, 2014, 35, 426-430.	1.0	123
50	Sexual Function in Persons With Inflammatory Bowel Disease: A Survey With Matched Controls. Clinical Gastroenterology and Hepatology, 2007, 5, 87-94.	2.4	122
51	Succinate receptor mediates intestinal inflammation and fibrosis. Mucosal Immunology, 2019, 12, 178-187.	2.7	122
52	Profiling adipocytokine secretion from creeping fat in Crohn's disease. Inflammatory Bowel Diseases, 2006, 12, 471-477.	0.9	118
53	Evidence for a role of epithelial mesenchymal transition during pathogenesis of fistulae in Crohn's disease. Inflammatory Bowel Diseases, 2008, 14, 1514-1527.	0.9	117
54	Analysis of intestinal haem-oxygenase-1 (HO-1) in clinical and experimental colitis. Clinical and Experimental Immunology, 2005, 140, 547-555.	1.1	115

#	Article	IF	CITATIONS
55	Comparison of magnetic resonance imaging colonography with conventional colonoscopy for the assessment of intestinal inflammation in patients with inflammatory bowel disease: a feasibility study. Gut, 2005, 54, 250-256.	6.1	112
56	Differential Protein Expression Profile in the Intestinal Epithelium from Patients with Inflammatory Bowel Disease. Journal of Proteome Research, 2007, 6, 1114-1125.	1.8	111
57	European society of neurogastroenterology and motility guidelines on functional constipation in adults. Neurogastroenterology and Motility, 2020, 32, e13762.	1.6	110
58	Morphological characterisation of Crohn's disease fistulae. Gut, 2004, 53, 1314-1321.	6.1	109
59	Interleukin-13 and transforming growth factor \hat{I}^2 synergise in the pathogenesis of human intestinal fistulae. Gut, 2013, 62, 63-72.	6.1	108
60	Hallmarks of epithelial to mesenchymal transition are detectable in Crohn's disease associated intestinal fibrosis. Clinical and Translational Medicine, 2015, 4, 1.	1.7	108
61	Development of an index to define overall disease severity in IBD. Gut, 2018, 67, 244-254.	6.1	108
62	Bilberry ingestion improves disease activity in mild to moderate ulcerative colitis — An open pilot study. Journal of Crohn's and Colitis, 2013, 7, 271-279.	0.6	106
63	Improvement of arthritis and arthralgia after treatment with infliximab (Remicade) in a German prospective, open-label, multicenter trial in refractory Crohn's disease. American Journal of Gastroenterology, 2002, 97, 2688-2690.	0.2	104
64	Cathepsins B, L and D in inflammatory bowel disease macrophages and potential therapeutic effects of cathepsin inhibition in vivo. Clinical and Experimental Immunology, 2006, 146, 169-180.	1.1	104
65	13-Oxo-ODE is an endogenous ligand for PPARÎ ³ in human colonic epithelial cells. Biochemical Pharmacology, 2007, 74, 612-622.	2.0	104
66	Diagnosis and management of fistulizing Crohn's disease. Nature Reviews Gastroenterology & Hepatology, 2009, 6, 92-106.	1.7	104
67	Pain in IBD Patients: Very Frequent and Frequently Insufficiently Taken into Account. PLoS ONE, 2016, 11, e0156666.	1.1	104
68	Identification of a SIRT1 Mutation in a Family with Type 1 Diabetes. Cell Metabolism, 2013, 17, 448-455.	7.2	103
69	Genome-Scale CRISPR Screening in Human Intestinal Organoids Identifies Drivers of TGF-β Resistance. Cell Stem Cell, 2020, 26, 431-440.e8.	5.2	103
70	Periodontitis and Gingivitis in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2013, 19, 2768-2777.	0.9	102
71	HDL-Mediated Efflux of Intracellular Cholesterol Is Impaired in Fibroblasts From Tangier Disease Patients. Arteriosclerosis, Thrombosis, and Vascular Biology, 1995, 15, 683-690.	1.1	101
72	Protection of Epithelial Barrier Function by the Crohn's Disease Associated Gene Protein Tyrosine Phosphatase N2. Gastroenterology, 2009, 137, 2030-2040.e5.	0.6	100

#	Article	IF	CITATIONS
73	Exposome in IBD. Inflammatory Bowel Diseases, 2015, 21, 400-408.	0.9	100
74	Cellular and Molecular Mediators of Intestinal Fibrosis. Journal of Crohn's and Colitis, 2017, 11, j.crohns.2014.09.008.	0.6	99
75	CpG Motifs of Bacterial DNA Essentially Contribute to the Perpetuation of Chronic Intestinal Inflammation. Gastroenterology, 2005, 129, 913-927.	0.6	98
76	The incidence of inflammatory bowel disease in a rural region of Southern Germany: a prospective population-based study. European Journal of Gastroenterology and Hepatology, 2008, 20, 917-923.	0.8	93
77	PTPN2 controls differentiation of CD4+ T cells and limits intestinal inflammation and intestinal dysbiosis. Mucosal Immunology, 2015, 8, 918-929.	2.7	93
78	Pathophysiology of fistula formation in Crohn's disease. World Journal of Gastrointestinal Pathophysiology, 2014, 5, 205.	0.5	93
79	Results of the Fifth Scientific Workshop of the ECCO (II): Pathophysiology of Perianal Fistulizing Disease. Journal of Crohn's and Colitis, 2016, 10, 377-386. Reduced migration of fibroblasts in inflammatory bowel disease: role of inflammatory mediators and	0.6	92
80	focal adhesion kinase1 1The authors thank Dr. Luitpold E. Miller for his assistance in the preparation of this manuscript; the doctors and nurses of the Endoscopy department; the surgeons and pathologists of the University of Regensburg, especially Dr. Frauke Bataille, for their ongoing great cooperation; and, most importantly, all patients who agreed to give biopsy and tissue samples,	0.6	91
81	without whom this study. Gastroenterology, 2003, 125, 1341-1354. Impact of the early use of immunomodulators or TNF antagonists on bowel damage and surgery in Crohn's disease. Alimentary Pharmacology and Therapeutics, 2015, 42, 977-989.	1.9	91
82	PTPN22 regulates NLRP3-mediated IL1B secretion in an autophagy-dependent manner. Autophagy, 2017, 13, 1590-1601.	4.3	90
83	Human intestinal epithelial cells secrete interleukin-1 receptor antagonist and interleukin-8 but not interleukin-1 or interleukin-6. Gut, 2000, 46, 350-358.	6.1	89
84	Milk oligosaccharide sialyl(α2,3)lactose activates intestinal CD11c ⁺ cells through TLR4. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 17444-17449.	3.3	89
85	Extraintestinal Manifestations of Pediatric Inflammatory Bowel Disease. Journal of Pediatric Gastroenterology and Nutrition, 2017, 65, 200-206.	0.9	89
86	Colectomy Rates in Ulcerative Colitis are Low and Decreasing: 10-year Follow-up Data From the Swiss IBD Cohort Study. Journal of Crohn's and Colitis, 2018, 12, 811-818.	0.6	88
87	Association of the novel serologic anti-glycan antibodies anti-laminarin and anti-chitin with complicated Crohn's disease behavior. Inflammatory Bowel Diseases, 2010, 16, 263-274.	0.9	87
88	Autophagy Gene Atg16l1 Prevents Lethal T Cell Alloreactivity Mediated by Dendritic Cells. Immunity, 2014, 41, 579-591.	6.6	87
89	Dark Lumen Magnetic Resonance Enteroclysis in Combination With Mri Colonography for Whole Bowel Assessment in Patients With Crohnɼs Disease: First Clinical Experience. Inflammatory Bowel Diseases, 2005, 11, 388-394.	0.9	81
90	PTPN2 Regulates Inflammasome Activation and Controls Onset of Intestinal Inflammation and Colon Cancer. Cell Reports, 2018, 22, 1835-1848.	2.9	80

#	Article	IF	CITATIONS
91	Serum anti-glycan antibodies predict complicated Crohn's disease behavior. Inflammatory Bowel Diseases, 2010, 16, 1367-1375.	0.9	79
92	Magnetization transfer for the assessment of bowel fibrosis in patients with Crohn's disease: initial experience. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2013, 26, 291-301.	1.1	79
93	Aluminum enhances inflammation and decreases mucosal healing in experimental colitis in mice. Mucosal Immunology, 2014, 7, 589-601.	2.7	78
94	Modern Imaging Using Computer Tomography and Magnetic Resonance Imaging for Inflammatory Bowel Disease (IBD) AU1. Inflammatory Bowel Diseases, 2004, 10, 45-54.	0.9	77
95	Transforming growth factor-β1 induces intestinal myofibroblast differentiation and modulates their migration. World Journal of Gastroenterology, 2009, 15, 1431.	1.4	77
96	Regulation of Migration of Human Colonic Myofibroblasts. Growth Factors, 2002, 20, 81-91.	0.5	75
97	Sphingomyelin induces cathepsin D-mediated apoptosis in intestinal epithelial cells and increases inflammation in DSS colitis. Gut, 2011, 60, 55-65.	6.1	74
98	Nuclear factor-κ B activity and intestinal inflammation in dextran sulphate sodium (DSS)-induced colitis in mice is suppressed by gliotoxin. Clinical and Experimental Immunology, 2000, 120, 59-65.	1.1	72
99	Protein tyrosine phosphatase N2 regulates TNFÂ-induced signalling and cytokine secretion in human intestinal epithelial cells. Gut, 2011, 60, 189-197.	6.1	72
100	Inflammatory bowel disease pathogenesis. Current Opinion in Gastroenterology, 2012, 28, 301-309.	1.0	72
101	Anti-TNF Treatment for Extraintestinal Manifestations of Inflammatory Bowel Disease in the Swiss IBD Cohort Study. Inflammatory Bowel Diseases, 2017, 23, 1174-1181.	0.9	72
102	Crohn's disease-associated polymorphism within the PTPN2 gene affects muramyl-dipeptide-induced cytokine secretion and autophagy. Inflammatory Bowel Diseases, 2012, 18, 900-912.	0.9	71
103	Bilberry-Derived Anthocyanins Modulate Cytokine Expression in the Intestine of Patients with Ulcerative Colitis. PLoS ONE, 2016, 11, e0154817.	1.1	71
104	Commensal Clostridiales strains mediate effective anti-cancer immune response against solid tumors. Cell Host and Microbe, 2021, 29, 1573-1588.e7.	5.1	71
105	Autologous stem-cell transplantation in treatment-refractory Crohn's disease: an analysis of pooled data from the ASTIC trial. The Lancet Gastroenterology and Hepatology, 2017, 2, 399-406.	3.7	70
106	Determinants of male sexual function in inflammatory bowel disease: A survey-based cross-sectional analysis in 280 men. Inflammatory Bowel Diseases, 2007, 13, 1236-1243.	0.9	69
107	Alterations of the phenotype of colonic macrophages in inflammatory bowel disease. European Journal of Gastroenterology and Hepatology, 1997, 9, 893-899.	0.8	68
108	Selecting End Points for Disease-Modification Trials in Inflammatory Bowel Disease: the SPIRIT Consensus From the IOIBD. Gastroenterology, 2021, 160, 1452-1460.e21.	0.6	68

#	Article	IF	CITATIONS
109	Update in inflammatory bowel disease pathogenesis. Current Opinion in Gastroenterology, 2004, 20, 311-317.	1.0	67
110	Vegetarian or glutenâ€free diets in patients with inflammatory bowel disease are associated with lower psychological wellâ€being and a different gut microbiota, but no beneficial effects on the course of the disease. United European Gastroenterology Journal, 2019, 7, 767-781.	1.6	67
111	Serum bile acid profiling reflects enterohepatic detoxification state and intestinal barrier function in in in inflammatory bowel disease. World Journal of Gastroenterology, 2009, 15, 3134.	1.4	67
112	Serum soluble TNF receptor I and II levels correlate with disease activity in IBD patients. Inflammatory Bowel Diseases, 2007, 13, 727-732.	0.9	66
113	Efficacy and Safety of Abrilumab in a Randomized, Placebo-Controlled Trial for Moderate-to-Severe Ulcerative Colitis. Gastroenterology, 2019, 156, 946-957.e18.	0.6	66
114	Inflammatory Bowel Disease: Dysfunction of Autophagy?. Digestive Diseases, 2012, 30, 12-19.	0.8	65
115	Crohn's disease: small bowel motility impairment correlates with inflammatoryâ€related markers Câ€reactive protein and calprotectin. Neurogastroenterology and Motility, 2013, 25, 467.	1.6	65
116	Helicobacter pylori–specific Protection Against Inflammatory Bowel Disease Requires the NLRP3 Inflammasome and IL-18. Inflammatory Bowel Diseases, 2015, 21, 854-861.	0.9	65
117	Anti-MMP-9 Antibody. Inflammatory Bowel Diseases, 2016, 22, 2041-2057.	0.9	64
118	Association of Alterations in Intestinal Microbiota With Impaired Psychological Function in Patients With Inflammatory Bowel Diseases in Remission. Clinical Gastroenterology and Hepatology, 2020, 18, 2019-2029.e11.	2.4	64
119	G Protein-coupled pH-sensing Receptor OGR1 Is a Regulator of Intestinal Inflammation. Inflammatory Bowel Diseases, 2015, 21, 1.	0.9	63
120	Clinical Relevance of IgG Antibodies against Food Antigens in Crohn's Disease: A Double-Blind Cross-Over Diet Intervention Study. Digestion, 2010, 81, 252-264.	1.2	62
121	Genetic susceptibility to increased bacterial translocation influences the response to biological therapy in patients with Crohn's disease. Gut, 2014, 63, 272-280.	6.1	62
122	Differential Activation of Cytokine Secretion in Primary Human Colonic Fibroblast/Myofibroblast Cultures. Scandinavian Journal of Gastroenterology, 2001, 36, 389-398.	0.6	61
123	Genetic variants in the NOD2/CARD15 gene are associated with early mortality in sepsis patients. Intensive Care Medicine, 2007, 33, 1541-1548.	3.9	60
124	Bilberries and their anthocyanins ameliorate experimental colitis. Molecular Nutrition and Food Research, 2011, 55, 1724-1729.	1.5	60
125	Protein Tyrosine Phosphatase Nonreceptor Type 2 Regulates Autophagosome Formation in Human Intestinal Cells. Inflammatory Bowel Diseases, 2012, 18, 1287-1302.	0.9	60
126	Human Colonic Myofibroblasts Promote Expansion of CD4+ CD25high Foxp3+ Regulatory T Cells. Gastroenterology, 2011, 140, 2019-2030.	0.6	59

#	Article	IF	CITATIONS
127	Systematic Assessment of Factors Influencing Preferences of Crohn's Disease Patients in Selecting an Anti-Tumor Necrosis Factor Agent (CHOOSE TNF TRIAL). Inflammatory Bowel Diseases, 2012, 18, 1523-1530.	0.9	59
128	The Trp64Arg Polymorphism of the 3-Adrenergic Receptor Gene Is Not Associated with Obesity or Type 2 Diabetes Mellitus in a Large Population-Based Caucasian Cohort. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 2892-2897.	1.8	59
129	Orofacial Granulomatosis as the Initial Presentation of Crohn's Disease in an Adolescent. Dermatology, 2003, 206, 273-278.	0.9	58
130	Functional Expression of the Interleukin-11 Receptor α-Chain and Evidence of Antiapoptotic Effects in Human Colonic Epithelial Cells. Journal of Biological Chemistry, 2004, 279, 10304-10315.	1.6	58
131	Mucosal healing and deep remission: What does it mean?. World Journal of Gastroenterology, 2013, 19, 7552.	1.4	58
132	Soluble galectin-3 is a strong, colonic epithelial-cell-derived, lamina propria fibroblast-stimulating factor. Gut, 2007, 56, 43-51.	6.1	57
133	Functional characterisation of decoy receptor 3 in Crohn's disease. Gut, 2009, 58, 483-491.	6.1	57
134	Prevalence of anaemia in inflammatory bowel disease in Switzerland: A cross-sectional study in patients from private practices and university hospitals. Journal of Crohn's and Colitis, 2010, 4, 642-648.	0.6	57
135	Anthocyanins Prevent Colorectal Cancer Development in a Mouse Model. Digestion, 2017, 95, 275-280.	1.2	56
136	Tumor necrosis factor stimulates fibroblast growth factor 23 levels in chronic kidney disease and non-renal inflammation. Kidney International, 2019, 96, 890-905.	2.6	56
137	Inducible CD40 expression mediates NFÂB activation and cytokine secretion in human colonic fibroblasts. Gut, 2003, 52, 1448-1456.	6.1	55
138	Epidermal Growth Factor Partially Restores Colonic Ion Transport Responses in Mouse Models of Chronic Colitis. Gastroenterology, 2005, 129, 591-608.	0.6	55
139	The Proton-activated Receptor GPR4 Modulates Intestinal Inflammation. Journal of Crohn's and Colitis, 2018, 12, 355-368.	0.6	55
140	Association of Perinuclear Antineutrophil Cytoplasmic Antibodies and Anti–Saccharomyces cerevisiae Antibodies With Vienna Classification Subtypes of Crohn's Disease. Inflammatory Bowel Diseases, 2003, 9, 302-307.	0.9	54
141	Recipient NOD2/CARD15 Variants: A Novel Independent Risk Factor for the Development of Bronchiolitis Obliterans after Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2008, 14, 67-74.	2.0	54
142	A Randomised, Double-blind, Placebo-controlled Trial of <i>Trichuris suis</i> ova in Active Crohn's disease. Journal of Crohn's and Colitis, 2017, 11, jjw184.	0.6	54
143	Risk factors for gallstones and kidney stones in a cohort of patients with inflammatory bowel diseases. PLoS ONE, 2017, 12, e0185193.	1.1	54
144	Mechanism-Based Treatment Strategies for IBD: Cytokines, Cell Adhesion Molecules, JAK Inhibitors, Gut Flora, and More. Inflammatory Intestinal Diseases, 2019, 4, 79-96.	0.8	53

#	Article	IF	CITATIONS
145	Topical therapy is underused in patients with ulcerative colitis. Journal of Crohn's and Colitis, 2014, 8, 56-63.	0.6	52
146	High Rates of Smoking Especially in Female Crohn's Disease Patients and Low Use of Supportive Measures to Achieve Smoking Cessation—Data from the Swiss IBD Cohort Study. Journal of Crohn's and Colitis, 2015, 9, 819-829.	0.6	52
147	Expression of Programmed Death-Ligand 1 by Human Colonic CD90+ Stromal Cells Differs Between Ulcerative Colitis and Crohn's Disease and Determines Their Capacity to Suppress Th1 Cells. Frontiers in Immunology, 2018, 9, 1125.	2.2	52
148	Long noncoding RNA H19X is a key mediator of TGF-β–driven fibrosis. Journal of Clinical Investigation, 2020, 130, 4888-4905.	3.9	52
149	Potential role for SNAIL family transcription factors in the etiology of Crohn's disease-associated fistulae. Inflammatory Bowel Diseases, 2011, 17, 1907-1916.	0.9	51
150	Resolution of inflammation in inflammatory bowel disease. The Lancet Gastroenterology and Hepatology, 2017, 2, 521-530.	3.7	51
151	Subtractive screening reveals up-regulation of NADPH oxidase expression in Crohn's disease intestinal macrophages. Clinical and Experimental Immunology, 2001, 125, 48-55.	1.1	50
152	Progress on isolation and short-term ex-vivo culture of highly purified non-apoptotic human intestinal epithelial cells (IEC). European Journal of Cell Biology, 2003, 82, 262-270.	1.6	50
153	Autocrine Fibronectin-Induced Migration of Human Colonic Fibroblasts. American Journal of Gastroenterology, 2004, 99, 335-340.	0.2	50
154	Cathepsin D is up-regulated in inflammatory bowel disease macrophages. Clinical and Experimental Immunology, 2004, 136, 157-167.	1.1	50
155	Intracellular Polyamine Levels of Intestinal Epithelial Cells in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2004, 10, 529-535.	0.9	50
156	Results of the 2nd Scientific Workshop of the ECCO (III): Basic mechanisms of intestinal healing. Journal of Crohn's and Colitis, 2012, 6, 373-375.	0.6	50
157	Burrowing is a sensitive behavioural assay for monitoring general wellbeing during dextran sulfate sodium colitis in laboratory mice. Laboratory Animals, 2013, 47, 274-283.	0.5	50
158	Long-term changes of bacterial and viral compositions in the intestine of a recovered <i>Clostridium difficile</i> patient after fecal microbiota transplantation. Journal of Physical Education and Sports Management, 2016, 2, a000448.	0.5	50
159	Irritable Bowel Syndrome Among a Cohort of European Travelers to Resourceâ€Limited Destinations. Journal of Travel Medicine, 2011, 18, 250-256.	1.4	49
160	Results of the Fifth Scientific Workshop of the ECCO [II]: Clinical Aspects of Perianal Fistulising Crohn's Disease—the Unmet Needs. Journal of Crohn's and Colitis, 2016, 10, 758-765.	0.6	49
161	Efficacy of JAK inhibitors in Crohn's Disease. Journal of Crohn's and Colitis, 2020, 14, S746-S754.	0.6	49
162	T-cell co-stimulatory molecules are upregulated on intestinal macrophages from inflammatory bowel disease mucosa. European Journal of Gastroenterology and Hepatology, 1999, 11, 1105-1112.	0.8	48

#	Article	lF	CITATIONS
163	Inhibition of proteasome activity by anthocyanins and anthocyanidins. Biochemical and Biophysical Research Communications, 2008, 372, 57-61.	1.0	48
164	Top-Down or Step-Up Treatment in Crohn's Disease?. Digestive Diseases, 2013, 31, 83-90.	0.8	48
165	Challenges in the Pathophysiology, Diagnosis, and Management of Intestinal Fibrosis in Inflammatory Bowel Disease. Gastroenterology, 2022, 162, 26-31.	0.6	48
166	Treatment Algorithms for Crohn's Disease. Digestion, 2020, 101, 43-57.	1.2	47
167	Possible Adverse Effects of Food Additive E171 (Titanium Dioxide) Related to Particle Specific Human Toxicity, Including the Immune System. International Journal of Molecular Sciences, 2021, 22, 207.	1.8	47
168	Loss of Protein Tyrosine Phosphatase Nonreceptor Type 22 Regulates Interferon-γ–Induced Signaling in Human Monocytes. Gastroenterology, 2013, 144, 978-988.e10.	0.6	46
169	Clucocorticoid receptors are down-regulated in inflamed colonic mucosa but not in peripheral blood mononuclear cells from patients with inflammatory bowel disease. European Journal of Clinical Investigation, 1999, 29, 330-336.	1.7	45
170	Monitoring colonoscopy withdrawal time significantly improves the adenoma detection rate and the performance of endoscopists. Endoscopy, 2016, 48, 256-262.	1.0	45
171	Patients with refractory Crohn's disease or ulcerative colitis respond to dehydroepiandrosterone: a pilot study. Alimentary Pharmacology and Therapeutics, 2003, 17, 409-414.	1.9	44
172	Crohn??s disease patient characteristics in a tertiary referral center: comparison with patients from a population-based cohort. European Journal of Gastroenterology and Hepatology, 2005, 17, 395-401.	0.8	44
173	Epidermal Growth Factor Partially Restores Colonic Ion Transport Responses in Mouse Models of Chronic Colitis. Gastroenterology, 2005, 129, 591-608.	0.6	44
174	Monocyte chemoattractant protein-1 (MCP-1) inhibits the intestinal-like differentiation of monocytes. Clinical and Experimental Immunology, 2006, 145, 190-199.	1.1	44
175	CpG-oligodeoxynucleotides stimulate immunoglobulin A secretion in intestinal mucosal B cells. Clinical and Experimental Immunology, 2009, 155, 534-540.	1.1	44
176	Association of genetic variation in the NR1H4 gene, encoding the nuclear bile acid receptor FXR, with inflammatory bowel disease. BMC Research Notes, 2012, 5, 461.	0.6	44
177	White-Light or Narrow-Band Imaging Colonoscopy in Surveillance of Ulcerative Colitis: A Prospective MulticenterÂStudy. Clinical Gastroenterology and Hepatology, 2015, 13, 1776-1781.e1.	2.4	44
178	Alicaforsen, an antisense inhibitor of ICAMâ€1, as treatment for chronic refractory pouchitis after proctocolectomy: A case series. United European Gastroenterology Journal, 2016, 4, 97-104.	1.6	44
179	Expression Patterns of TNFα, MAdCAM1, and STAT3 in Intestinal and Skin Manifestations of Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2018, 12, 347-354.	0.6	44
180	Expression of growth factor receptors and targeting of EGFR in cholangiocarcinoma cell lines. BMC Cancer, 2010, 10, 302.	1.1	43

#	Article	IF	CITATIONS
181	Association of antibodies to exocrine pancreas with subtypes of Crohn's disease. European Journal of Gastroenterology and Hepatology, 2005, 17, 73-77.	0.8	42
182	BCL-2 Modifying Factor (BMF) Is a Central Regulator of Anoikis in Human Intestinal Epithelial Cells. Journal of Biological Chemistry, 2011, 286, 26533-26540.	1.6	42
183	β ₆ â€integrin serves as a novel serum tumor marker for colorectal carcinoma. International Journal of Cancer, 2019, 145, 678-685.	2.3	42
184	Concept for a rapid point-of-care calprotectin diagnostic test for diagnosis and disease activity monitoring in patients with inflammatory bowel disease: Expert clinical opinion. Journal of Crohn's and Colitis, 2013, 7, 670-677.	0.6	41
185	Fc Gamma Receptor CD64 Modulates the Inhibitory Activity of Infliximab. PLoS ONE, 2012, 7, e43361.	1.1	41
186	Growth and Cell Cycle Abnormalities of Fibroblasts From Tangier Disease Patients. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 28-38.	1.1	40
187	First-Line Therapies in Inflammatory Bowel Disease. Digestion, 2012, 86, 6-10.	1.2	40
188	Decreased Fibrogenesis After Treatment with Pirfenidone in a Newly Developed Mouse Model of Intestinal Fibrosis. Inflammatory Bowel Diseases, 2016, 22, 569-582.	0.9	40
189	Upper Gastrointestinal Tract Involvement in Crohn's Disease: Frequency, Risk Factors, and Disease Course. Journal of Crohn's and Colitis, 2018, 12, 1399-1409.	0.6	40
190	The EBI2-oxysterol axis promotes the development of intestinal lymphoid structures and colitis. Mucosal Immunology, 2019, 12, 733-745.	2.7	40
191	Mutant HRAS as novel target for MEK and mTOR inhibitors. Oncotarget, 2015, 6, 42183-42196.	0.8	40
192	Role of biological therapy for inflammatory bowel disease in developing countries. Gut, 2012, 61, 706-712.	6.1	39
193	Association of extraintestinal manifestations and anaemia with disease outcomes in patients with inflammatory bowel disease. Scandinavian Journal of Gastroenterology, 2016, 51, 848-854.	0.6	39
194	Lack of the pH-sensing Receptor TDAG8 [GPR65] in Macrophages Plays a Detrimental Role in Murine Models of Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2019, 13, 245-258.	0.6	39
195	Malignancies in Inflammatory Bowel Disease: Frequency, Incidence and Risk Factors—Results from the Swiss IBD Cohort Study. American Journal of Gastroenterology, 2019, 114, 116-126.	0.2	39
196	IL-15 protects intestinal epithelial cells. European Journal of Immunology, 2006, 36, 2691-2699.	1.6	38
197	Association of the NOD2 genotype with bacterial translocation via altered cell–cell contacts in Crohn's disease patients. Inflammatory Bowel Diseases, 2010, 16, 1311-1321.	0.9	38
198	A role for interleukin-33 in TH2-polarized intestinal inflammation?. Mucosal Immunology, 2011, 4, 496-502.	2.7	38

#	Article	IF	CITATIONS
199	Systematic Analysis of the Impact of Diagnostic Delay on Bowel Damage in Paediatric Versus Adult Onset Crohn's Disease. Journal of Crohn's and Colitis, 2019, 13, 1334-1342.	0.6	38
200	The Evolution of Health Care Utilisation and Costs for Inflammatory Bowel Disease Over Ten Years. Journal of Crohn's and Colitis, 2019, 13, 744-754.	0.6	38
201	Dysbiotic microbiota interactions in Crohn's disease. Gut Microbes, 2021, 13, 1949096.	4.3	38
202	Protein Tyrosine Phosphatase Non-Receptor Type 22 Modulates NOD2-Induced Cytokine Release and Autophagy. PLoS ONE, 2013, 8, e72384.	1.1	38
203	Ephrin-B2 is differentially expressed in the intestinal epithelium in Crohn's disease and contributes to accelerated epithelial wound healingin vitro. World Journal of Gastroenterology, 2005, 11, 4024.	1.4	38
204	Do We Need Gastric Acid?. Digestion, 2008, 77, 184-197.	1.2	37
205	Recent Advances Using Immunomodulators for Inflammatory Bowel Disease. Journal of Clinical Pharmacology, 2013, 53, 575-588.	1.0	37
206	High altitude journeys and flights are associated with an increased risk of flares in inflammatory bowel disease patients. Journal of Crohn's and Colitis, 2014, 8, 191-199.	0.6	37
207	Elevated oxysterol levels in human and mouse livers reflect nonalcoholic steatohepatitis. Journal of Lipid Research, 2019, 60, 1270-1283.	2.0	37
208	Early Initiation of Anti-TNF is Associated with Favourable Long-term Outcome in Crohn's Disease: 10-Year-Follow-up Data from the Swiss IBD Cohort Study. Journal of Crohn's and Colitis, 2019, 13, 1292-1301.	0.6	37
209	Regulation of galectin-3 function in mucosal fibroblasts: potential role in mucosal inflammation. Clinical and Experimental Immunology, 2008, 152, 285-297.	1.1	36
210	Partial Replacement of Dietary (n-6) Fatty Acids with Medium-Chain Triglycerides Decreases the Incidence of Spontaneous Colitis in Interleukin-10–Deficient Mice. Journal of Nutrition, 2009, 139, 603-610.	1.3	36
211	CYP3A4-Catalyzed Simvastatin Metabolism as a Non-Invasive Marker of Small Intestinal Health in Celiac Disease. American Journal of Gastroenterology, 2013, 108, 1344-1351.	0.2	36
212	Activation of Protein Tyrosine Phosphatase Non-Receptor Type 2 by Spermidine Exerts Anti-Inflammatory Effects in Human THP-1 Monocytes and in a Mouse Model of Acute Colitis. PLoS ONE, 2013, 8, e73703.	1.1	36
213	Biologics for Extraintestinal Manifestations of IBD. Current Drug Targets, 2014, 15, 1064-1073.	1.0	36
214	Epithelial-to-mesenchymal transition in a fistula-associated anal adenocarcinoma in a patient with long-standing Crohn's disease. European Journal of Gastroenterology and Hepatology, 2014, 26, 114-118.	0.8	36
215	Where are we heading to in pharmacological IBD therapy?. Pharmacological Research, 2015, 100, 220-227.	3.1	36
216	Low allopurinol doses are sufficient to optimize azathioprine therapy in inflammatory bowel disease patients with inadequate thiopurine metabolite concentrations. European Journal of Clinical Pharmacology, 2013, 69, 1521-1531.	0.8	35

#	Article	IF	CITATIONS
217	Apoptotic enteropathy caused by antimetabolites and TNF-α antagonists. Journal of Clinical Pathology, 2014, 67, 582-586.	1.0	35
218	Experts Opinion on the Practical Use of Azathioprine and 6-Mercaptopurine in Inflammatory Bowel Diseases, 2016, 22, 2733-2747.	0.9	35
219	The Search for Causative Environmental Factors in Inflammatory Bowel Disease. Digestive Diseases, 2016, 34, 48-55.	0.8	35
220	Prdx6 Deficiency Ameliorates DSS Colitis: Relevance of Compensatory Antioxidant Mechanisms. Journal of Crohn's and Colitis, 2017, 11, 871-884.	0.6	35
221	The presence of genetic risk variants within PTPN2 and PTPN22 is associated with intestinal microbiota alterations in Swiss IBD cohort patients. PLoS ONE, 2018, 13, e0199664.	1.1	35
222	Information Needs and Concerns of Patients with Inflammatory Bowel Disease: What Can We Learn from Participants in a Bilingual Clinical Cohort?. PLoS ONE, 2016, 11, e0150620.	1.1	35
223	Inverse regulation of the ADAM-family members, decysin and MADDAM/ADAM19 during monocyte differentiation. Immunology, 2003, 110, 450-457.	2.0	34
224	Bile salt-induced apoptosis in human colon cancer cell lines involves the mitochondrial transmembrane potential but not the CD95 (Fas/Apo-1) receptor. International Journal of Colorectal Disease, 2005, 20, 103-113.	1.0	34
225	Use of biological molecules in the treatment of inflammatory bowel disease. Journal of Internal Medicine, 2011, 270, 15-28.	2.7	34
226	Probiotic <i>Escherichia coli</i> Nissle 1917 and Commensal <i>E. coli</i> K12 Differentially Affect the Inflammasome in Intestinal Epithelial Cells. Digestion, 2014, 89, 110-118.	1.2	34
227	Pushing the Pedal to the Metal: Should We Accelerate Infliximab Therapy for Patients With Severe Ulcerative Colitis?. Clinical Gastroenterology and Hepatology, 2015, 13, 336-338.	2.4	34
228	Hypoxia Positively Regulates the Expression of pH-Sensing G-Protein–Coupled Receptor OGR1 (GPR68). Cellular and Molecular Gastroenterology and Hepatology, 2016, 2, 796-810.	2.3	34
229	Gut Bacterial DNA Translocation is an Independent Risk Factor of Flare at Short Term in Patients With Crohn's Disease. American Journal of Gastroenterology, 2016, 111, 529-540.	0.2	34
230	Identification of Endpoints for Development of Antifibrosis Drugs for Treatment of Crohn's Disease. Gastroenterology, 2018, 155, 76-87.	0.6	34
231	Prostaglandin E2 inhibits migration of colonic lamina propria fibroblasts. Inflammatory Bowel Diseases, 2010, 16, 1505-1513.	0.9	33
232	Specific differences in migratory function of myofibroblasts isolated from Crohn's disease fistulae and strictures. Inflammatory Bowel Diseases, 2011, 17, 202-212.	0.9	33
233	Penetrating or Stricturing Diseases are the Major Determinants of Time to First and Repeat Resection Surgery in Crohn's Disease. Digestion, 2013, 87, 212-221.	1.2	33
234	Analysis of the Intestinal Microbiome of a Recovered <i>Clostridium difficile</i> Patient after Fecal Transplantation. Digestion, 2013, 88, 243-251.	1.2	33

#	Article	IF	CITATIONS
235	Bilberry-Derived Anthocyanins Prevent IFN-γ-Induced Pro-Inflammatory Signalling and Cytokine Secretion in Human THP-1 Monocytic Cells. Digestion, 2014, 90, 179-189.	1.2	33
236	Anti-inflammatory Function of High-Density Lipoproteins via Autophagy of IκB Kinase. Cellular and Molecular Gastroenterology and Hepatology, 2015, 1, 171-187.e1.	2.3	33
237	Anemia in Inflammatory Bowel Disease: An Under-Estimated Problem?. Frontiers in Medicine, 2014, 1, 58.	1.2	33
238	The pH-sensing receptor OGR1 improves barrier function of epithelial cells and inhibits migration in an acidic environment. American Journal of Physiology - Renal Physiology, 2015, 309, G475-G490.	1.6	33
239	Secretion of RANTES (CCL5) and interleukin-10 from mesenteric adipose tissue and from creeping fat in Crohn's disease: Regulation by steroid treatment. Journal of Gastroenterology and Hepatology (Australia), 2006, 21, 060606032707058-???.	1.4	32
240	Use of thiopurines in inflammatory bowel disease. World Journal of Gastroenterology, 2013, 19, 1040.	1.4	32
241	Risk Factors for Repetitive Ileocolic Resection in Patients with Crohn's Disease. Inflammatory Bowel Diseases, 2014, 20, 1548-1554.	0.9	32
242	Role of Protein Tyrosine Phosphatases in Regulating the Immune System. Inflammatory Bowel Diseases, 2015, 21, 645-655.	0.9	32
243	Severe Sweet's Syndrome with Elevated Cutaneous Interleukin-1β after Azathioprine Exposure: Case Report and Review of the Literature. Dermatology, 2015, 230, 293-298.	0.9	32
244	The Relevance of Vitamin and Iron Deficiency in Patients with Inflammatory Bowel Diseases in Patients of the Swiss IBD Cohort. Inflammatory Bowel Diseases, 2018, 24, 1768-1779.	0.9	32
245	Activation of pH-Sensing Receptor OGR1 (GPR68) Induces ER Stress Via the IRE1α/JNK Pathway in an Intestinal Epithelial Cell Model. Scientific Reports, 2020, 10, 1438.	1.6	32
246	Targeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma. PLoS ONE, 2016, 11, e0147682.	1.1	32
247	Polymorphism of monocyte chemoattractant protein 1 in Crohn's disease. International Journal of Colorectal Disease, 2003, 18, 401-405.	1.0	31
248	Stimulation of human colonic epithelial cells by leukemia inhibitory factor is dependent on collagenâ€embedded fibroblasts in organotypic culture. FASEB Journal, 2003, 17, 1115-1117.	0.2	31
249	Hepatic failure due to hepatitis B reactivation in a patient with ulcerative colitis treated with prednisone. Hepatology, 2009, 50, 653-654.	3.6	31
250	Inflammatory Bowel Disease Cancer Risk, Detection and Surveillance. Digestive Diseases, 2012, 30, 48-54.	0.8	31
251	The effects of vitamin A on cells of innate immunity in vitro. Toxicology in Vitro, 2013, 27, 1525-1532.	1.1	31
252	Heat Waves, Incidence of Infectious Gastroenteritis, and Relapse Rates of Inflammatory Bowel Disease: A Retrospective Controlled Observational Study. American Journal of Gastroenterology, 2013, 108, 1480-1485.	0.2	31

#	Article	IF	CITATIONS
253	The effectiveness and safety of rescue treatments in 108 patients with steroid-refractory ulcerative colitis with sequential rescue therapies in a subgroup of patients. Journal of Crohn's and Colitis, 2014, 8, 1427-1437.	0.6	31
254	The Impact of Azathioprine-Associated Lymphopenia on the Onset of Opportunistic Infections in Patients with Inflammatory Bowel Disease. PLoS ONE, 2016, 11, e0155218.	1.1	31
255	Identification of oncogenic driver mutations by genome-wide CRISPR-Cas9 dropout screening. BMC Genomics, 2016, 17, 723.	1.2	31
256	Efficacy of Endoscopic Dilation of Gastroduodenal Crohn's Disease Strictures: A Systematic Review and Meta-Analysis of Individual Patient Data. Clinical Gastroenterology and Hepatology, 2019, 17, 2514-2522.e8.	2.4	31
257	Therapy of Steroid-Resistant Inflammatory Bowel Disease. Digestion, 2012, 86, 11-15.	1.2	30
258	Celiac disease diagnosis still significantly delayed – Doctor's but not patients' delay responsive for the increased total delay in women. Digestive and Liver Disease, 2016, 48, 1148-1154.	0.4	30
259	Frequency and type of drug-related side effects necessitating treatment discontinuation in the Swiss Inflammatory Bowel Disease Cohort. European Journal of Gastroenterology and Hepatology, 2018, 30, 612-620.	0.8	30
260	Exogenous sphingomyelinase causes impaired intestinal epithelial barrier function. World Journal of Gastroenterology, 2007, 13, 5217.	1.4	30
261	Recipient NOD2/CARD15 status affects cellular infiltrates in human intestinal graft- <i>versus</i> -host disease. Clinical and Experimental Immunology, 2009, 159, 87-92.	1.1	29
262	Topical Therapies in Inflammatory Bowel Disease. Digestion, 2012, 86, 36-44.	1.2	29
263	Microparticles and Their Impact on Intestinal Immunity. Digestive Diseases, 2012, 30, 47-54.	0.8	29
264	Downregulation of duodenal SLC transporters and activation of proinflammatory signaling constitute the early response to high altitude in humans. American Journal of Physiology - Renal Physiology, 2014, 307, G673-G688.	1.6	29
265	Intestinal Activation of pH-Sensing Receptor OGR1 [GPR68] Contributes to Fibrogenesis. Journal of Crohn's and Colitis, 2018, 12, 1348-1358.	0.6	29
266	Vaccination in Patients with Inflammatory Bowel Diseases. Digestion, 2020, 101, 58-68.	1.2	29
267	Characterization of Changes in Serum Anti-Glycan Antibodies in Crohn's Disease – a Longitudinal Analysis. PLoS ONE, 2011, 6, e18172.	1.1	29
268	The Role for Dickkopf-Homolog-1 in the Pathogenesis of Crohn's Disease-Associated Fistulae. PLoS ONE, 2013, 8, e78882.	1.1	28
269	Protein tyrosine phosphatase non-receptor type 2 and inflammatory bowel disease. World Journal of Gastroenterology, 2016, 22, 1034.	1.4	28
270	Multiparameter Immunofluorescence on Paraffin-Embedded Tissue Sections. Applied Immunohistochemistry and Molecular Morphology, 2006, 14, 225-228.	0.6	27

#	Article	IF	CITATIONS
271	Efficacy and safety of certolizumab pegol induction therapy in an unselected Crohn's disease population. Inflammatory Bowel Diseases, 2010, 16, 933-938.	0.9	27
272	A Role for Tumor Necrosis Factor and Bacterial Antigens in the Pathogenesis of Crohn's Disease–Associated Fistulae. Inflammatory Bowel Diseases, 2013, 19, 2878-2887.	0.9	27
273	Transcriptional Analysis of Left-sided Colitis, Pancolitis, and Ulcerative Colitis-associated Dysplasia. Inflammatory Bowel Diseases, 2014, 20, 2340-2352.	0.9	27
274	The role and advances of immunomodulator therapy for inflammatory bowel disease. Expert Review of Gastroenterology and Hepatology, 2015, 9, 177-189.	1.4	27
275	Effects of oral antibiotics and isotretinoin on the murine gut microbiota. International Journal of Antimicrobial Agents, 2017, 50, 342-351.	1.1	27
276	Management of the Elderly Inflammatory Bowel Disease Patient. Digestion, 2020, 101, 105-119.	1.2	27
277	New insights into the pathophysiology of inflammatory bowel disease: microbiota, epigenetics and common signalling pathways. Swiss Medical Weekly, 2018, 148, w14599.	0.8	27
278	Glycoprotein (gp) 96 expression: induced during differentiation of intestinal macrophages but impaired in Crohn's disease. Gut, 2005, 54, 935-943.	6.1	26
279	Collagen XVI induces formation of focal contacts on intestinal myofibroblasts isolated from the normal and inflamed intestinal tract. Matrix Biology, 2010, 29, 177-193.	1.5	26
280	Muramyl dipeptide responsive pathways in Crohn's disease: from NOD2 and beyond. Cellular and Molecular Life Sciences, 2013, 70, 3391-3404.	2.4	26
281	Widely differing screening and treatment practice for osteoporosis in patients with inflammatory bowel diseases in the Swiss IBD cohort study. Medicine (United States), 2017, 96, e6788.	0.4	26
282	The Management of Inflammatory Bowel Disease in Elderly: Current Evidence and Future Perspectives. Inflammatory Intestinal Diseases, 2017, 2, 189-199.	0.8	26
283	Cohort Profile Update: The Swiss Inflammatory Bowel Disease Cohort Study (SIBDCS). International Journal of Epidemiology, 2019, 48, 385-386f.	0.9	26
284	Occurrence of skin manifestations in patients of the Swiss Inflammatory Bowel Disease Cohort Study. PLoS ONE, 2019, 14, e0210436.	1.1	26
285	A Multicentre, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of the S1P Receptor Agonist KRP203 in Patients with Moderately Active Refractory Ulcerative Colitis. Inflammatory Intestinal Diseases, 2020, 5, 180-190.	0.8	26
286	Evidence for a differential expression of fibronectin splice forms ED-A and ED-B in Crohn's disease (CD) mucosa. International Journal of Colorectal Disease, 2007, 22, 611-623.	1.0	25
287	Decreased Cytosolic Glucocorticoid Receptor Levels in Critically Ill Patients. Anaesthesia and Intensive Care, 2010, 38, 133-140.	0.2	25
288	Hemoglobin and Hematocrit Levels in the Prediction of Complicated Crohn's Disease Behavior – A Cohort Study. PLoS ONE, 2014, 9, e104706.	1.1	25

#	Article	IF	CITATIONS
289	Monitoring Disease Activity and Progression in Crohn's Disease. A Swiss Perspective on the IBD Ahead â€~Optimised Monitoring' Recommendations. Digestion, 2014, 89, 299-309.	1.2	25
290	Serologic Anti-GP2 Antibodies Are Associated with Genetic Polymorphisms, Fibrostenosis, and Need for Surgical Resection in Crohn's Disease. Inflammatory Bowel Diseases, 2016, 22, 2648-2657.	0.9	25
291	Clinical manifestations, pathophysiology, treatment and outcome of inflammatory bowel diseases in older people. Maturitas, 2018, 110, 71-78.	1.0	25
292	Fatigue in inflammatory bowel disease and its impact on daily activities. Alimentary Pharmacology and Therapeutics, 2021, 53, 138-149.	1.9	25
293	High-density lipoprotein 3 retroendocytosis: A new lipoprotein pathway in the enterocyte (Caco-2). Gastroenterology, 1992, 103, 469-480.	0.6	24
294	Intestinal Absorption and Vitamin Levels: Is a New Focus Needed?. Digestive Diseases, 2012, 30, 73-80.	0.8	24
295	Clinical Utility of Anti-Glycan Antibodies in Pediatric Crohn's Disease in Comparison with An Adult Cohort. Inflammatory Bowel Diseases, 2012, 18, 1221-1231.	0.9	24
296	Fistulizing Crohn's Disease. Clinical and Translational Gastroenterology, 2017, 8, e106.	1.3	24
297	Factors Promoting Development of Fibrosis in Crohn's Disease. Frontiers in Medicine, 2017, 4, 96.	1.2	24
298	The impact of the rs8005161 polymorphism on G protein-coupled receptor GPR65 (TDAG8) pH-associated activation in intestinal inflammation. BMC Gastroenterology, 2019, 19, 2.	0.8	24
299	Impact of obesity on disease activity and disease outcome in inflammatory bowel disease: Results from the Swiss inflammatory bowel disease cohort. United European Gastroenterology Journal, 2020, 8, 1196-1207.	1.6	24
300	Efficacy and safety of certolizumab pegol in an unselected crohn's disease population. Inflammatory Bowel Diseases, 2011, 17, 1530-1539.	0.9	23
301	Hypoxia Induces the Expression of Transketolase-Like 1 in Human Colorectal Cancer. Digestion, 2013, 88, 182-192.	1.2	23
302	Crohn's Disease: Loss of Tolerance or a Disorder of Autophagy?. Digestive Diseases, 2014, 32, 370-377.	0.8	23
303	Systematic analysis of factors associated with progression and regression of ulcerative colitis in 918 patients. Alimentary Pharmacology and Therapeutics, 2015, 42, 540-548.	1.9	23
304	Clinical Utility of Biomarkers in IBD. Current Gastroenterology Reports, 2015, 17, 26.	1.1	23
305	Efficacy and safety of methotrexate in the management of inflammatory bowel disease: A systematic review and meta-analysis of randomized, controlled trials. EClinicalMedicine, 2020, 20, 100271.	3.2	23
306	Optimising the diagnostic value of Anti- Saccharomyces cerevisiae -antibodies (ASCA) in Crohn?s disease. International Journal of Colorectal Disease, 2004, 19, 319-324.	1.0	22

#	Article	IF	CITATIONS
307	Association between Cogan's syndrome and inflammatory bowel disease: A case series. Journal of Crohn's and Colitis, 2011, 5, 64-68.	0.6	22
308	Betaâ€glucosidase 2 knockout mice with increased glucosylceramide show impaired liver regeneration. Liver International, 2012, 32, 1354-1362.	1.9	22
309	A New Heterotopic Transplant Animal Model of Intestinal Fibrosis. Inflammatory Bowel Diseases, 2013, 19, 2302-2314.	0.9	22
310	Cogan's Syndrome in Patients With Inflammatory Bowel Disease – A Case Series. Journal of Crohn's and Colitis, 2015, 9, 886-890.	0.6	22
311	High Altitude Journeys, Flights and Hypoxia: Any Role for Disease Flares in IBD Patients?. Digestive Diseases, 2016, 34, 78-83.	0.8	22
312	Cell-specific Activation of the Nrf2 Antioxidant Pathway Increases Mucosal Inflammation in Acute but Not in Chronic Colitis. Journal of Crohn's and Colitis, 2016, 11, jjw172.	0.6	22
313	Doxycycline, metronidazole and isotretinoin: Do they modify microRNA/mRNA expression profiles and function in murine T-cells?. Scientific Reports, 2016, 6, 37082.	1.6	22
314	Strong expression of methylthioadenosine phosphorylase (MTAP) in human colon carcinoma cells is regulated by TCF1/[beta]-catenin. Laboratory Investigation, 2005, 85, 124-136.	1.7	21
315	The role of domestic hygiene in inflammatory bowel diseases: hepatitis A and worm infestations. European Journal of Gastroenterology and Hepatology, 2008, 20, 561-566.	0.8	21
316	Medical Management of Ulcerative Colitis. Digestive Diseases, 2009, 27, 542-549.	0.8	21
317	Fistula Treatment: The Unresolved Challenge. Digestive Diseases, 2010, 28, 556-564.	0.8	21
318	Pregnancy and Breastfeeding in Inflammatory Bowel Disease. Digestion, 2012, 86, 45-54.	1.2	21
319	Prediction of low bone mineral density in patients with inflammatory bowel diseases. United European Gastroenterology Journal, 2016, 4, 669-676.	1.6	21
320	Loss of PTPN22 abrogates the beneficial effect of cohousing-mediated fecal microbiota transfer in murine colitis. Mucosal Immunology, 2019, 12, 1336-1347.	2.7	21
321	Systematic Evaluation of Diagnostic Delay in Pediatric Inflammatory Bowel Disease. Journal of Pediatric Gastroenterology and Nutrition, 2017, 64, 245-247.	0.9	20
322	Uveitis manifestations in patients of the Swiss Inflammatory Bowel Disease Cohort Study. Therapeutic Advances in Gastroenterology, 2019, 12, 175628481986514.	1.4	20
323	Nutritional Lipids and Mucosal Inflammation. Molecular Nutrition and Food Research, 2021, 65, e1901269.	1.5	20
324	Depressive Symptoms Predict Clinical Recurrence of Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2022, 28, 560-571.	0.9	20

#	Article	IF	CITATIONS
325	Frequency and Nature of Incidental Extra-Enteric Lesions Found on Magnetic Resonance Enterography (MR-E) in Patients with Inflammatory Bowel Diseases (IBD). PLoS ONE, 2009, 4, e4863.	1.1	20
326	Ingested nano- and microsized polystyrene particles surpass the intestinal barrier and accumulate in the body. NanoImpact, 2022, 25, 100374.	2.4	20
327	Physiological Role of Macrophage Inflammatory Protein-3α Induction during Maturation of Intestinal Macrophages. Journal of Immunology, 2005, 175, 1389-1398.	0.4	19
328	Glucocorticoid receptor isoform expression does not predict steroid treatment response in IBD. Gut, 2007, 56, 1328-1329.	6.1	19
329	Increased lymphocyte apoptosis in mouse models of colitis upon ABT-737 treatment is dependent upon BIM expression. Clinical and Experimental Immunology, 2015, 181, 343-356.	1.1	19
330	Administration of the Hyper-immune Bovine Colostrum Extract IMM-124E Ameliorates Experimental Murine Colitis. Journal of Crohn's and Colitis, 2019, 13, 785-797.	0.6	19
331	Allogeneic expanded adiposeâ€derived mesenchymal stem cell therapy for perianal fistulas in Crohn's disease: A case series. Colorectal Disease, 2021, 23, 1444-1450.	0.7	19
332	Review: New Anti-Cytokines for IBD: What is in the Pipeline?. Current Drug Targets, 2013, 14, 1405-1420.	1.0	19
333	Clinical Experience with Adalimumab in a Multicenter Swiss Cohort of Patients with Crohn's Disease. Digestion, 2010, 81, 78-85.	1.2	18
334	Interaction between Susceptibility and Environment: Examples from the Digestive Tract. Digestive Diseases, 2011, 29, 136-143.	0.8	18
335	Downregulation of the Ubiquitin-Proteasome System in Normal Colonic Macrophages and Reinduction in Inflammatory Bowel Disease. Digestion, 2012, 86, 34-47.	1.2	18
336	Mucosal Healing with Anti-TNF Antibodies. Digestion, 2012, 86, 16-22.	1.2	18
337	Induction or Exacerbation of Psoriasis in Patients with Crohn's Disease under Treatment with Anti-TNF Antibodies. Digestion, 2014, 89, 209-215.	1.2	18
338	Species-specific engagement of human nucleotide oligomerization domain 2 (NOD)2 and Toll-like receptor (TLR) signalling upon intracellular bacterial infection: role of Crohn's associated NOD2 gene variants. Clinical and Experimental Immunology, 2015, 179, 426-434.	1.1	18
339	Clinicopathological and Molecular Specificities of Inflammatory Bowel Disease–Related Colorectal Neoplastic Lesions: The Role of Inflammation. Journal of Crohn's and Colitis, 2018, 12, 1486-1498.	0.6	18
340	Rapid expansion of Treg cells protects from collateral colitis following a viral trigger. Nature Communications, 2020, 11, 1522.	5.8	18
341	Tofacitinib, an Oral Janus Kinase Inhibitor: Analysis of Malignancy (Excluding Nonmelanoma Skin) Tj ETQq1 1 0.7 816-825.	84314 rgB 0.9	T /Overlock 1 18
342	Endpoints for extraintestinal manifestations in inflammatory bowel disease trials: the EXTRA consensus from the International Organization for the Study of Inflammatory Bowel Diseases. The Lancet Gastroenterology and Hepatology, 2022, 7, 254-261.	3.7	18

#	Article	IF	CITATIONS
343	Influence of Cholesterol Supply on Cell Growth and Differentiation in Cultured Enterocytes (CaCo-2). Digestion, 1995, 56, 57-66.	1.2	17
344	Vascular endothelial growth factor secretion from mesenteric adipose tissue and from creeping fat in Crohn's disease. Journal of Gastroenterology and Hepatology (Australia), 2006, 21, 060606032707048-???.	1.4	17
345	A case of recurrent gastrointestinal bleeding and protein-losing gastroenteropathy. Nature Reviews Gastroenterology & Hepatology, 2007, 4, 288-293.	1.7	17
346	The effects of NOD2/CARD15 mutations on the function of the intestinal barrier. Journal of Crohn's and Colitis, 2007, 1, 53-60.	0.6	17
347	Treatment of Severe Ulcerative Colitis: Differences in Elderly Patients?. Digestive Diseases, 2009, 27, 315-321.	0.8	17
348	Afferent nerve sensitivity is decreased by an iNOSâ€dependent mechanism during indomethacinâ€induced inflammation in the murine jejunum <i>in vitro</i> . Neurogastroenterology and Motility, 2009, 21, 322-334.	1.6	17
349	Microbial Sensing by the Intestinal Epithelium in the Pathogenesis of Inflammatory Bowel Disease. International Journal of Inflammation, 2010, 2010, 1-12.	0.9	17
350	Patients' information-seeking activity is associated with treatment compliance in inflammatory bowel disease patients. Scandinavian Journal of Gastroenterology, 2014, 49, 662-673.	0.6	17
351	Sphingomyelin and phosphatidylcholine contrarily affect the induction of apoptosis in intestinal epithelial cells. Molecular Nutrition and Food Research, 2014, 58, 782-798.	1.5	17
352	Patients' views on fecal microbiota transplantation: an acceptable therapeutic option in inflammatory bowel disease?. European Journal of Gastroenterology and Hepatology, 2017, 29, 322-330.	0.8	17
353	Preventive Trichuris suis ova (TSO) treatment protects immunocompetent rabbits from DSS colitis but may be detrimental under conditions of immunosuppression. Scientific Reports, 2017, 7, 16500.	1.6	17
354	BCL2 Regulates Differentiation of Intestinal Fibroblasts. Inflammatory Bowel Diseases, 2018, 24, 1953-1966.	0.9	17
355	Retrospective Analysis of Treatment and Complications of Immune Checkpoint Inhibitor-Associated Colitis: Histological Ulcerations as Potential Predictor for a Steroid-Refractory Disease Course. Inflammatory Intestinal Diseases, 2020, 5, 109-116.	0.8	17
356	Association of HLA-DR genotypes and IL-1ra gene polymorphism with treatment failure of budesonide and disease patterns in Crohn's disease. European Journal of Gastroenterology and Hepatology, 2001, 13, 1431-1437.	0.8	16
357	Inflammation modulates fibronectin isoform expression in colonic lamina propria fibroblasts (CLPF). International Journal of Colorectal Disease, 2008, 23, 947-955.	1.0	16
358	NOD2/CARD15 Polymorphisms in Allogeneic Stem-Cell Transplantation From Unrelated Donors: T Depletion Matters. Journal of Clinical Oncology, 2008, 26, 338-339.	0.8	16
359	The two sides of the coin: Similarities and differences in the pathomechanisms of fistulas and stricture formations in irritable bowel disease. United European Gastroenterology Journal, 2016, 4, 506-514.	1.6	16
360	Protein tyrosine phosphatase nonreceptor type 2 controls colorectal cancer development. Journal of Clinical Investigation, 2021, 131, .	3.9	16

#	Article	IF	CITATIONS
361	Type D personality is associated with depressive symptoms and clinical activity in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2021, 54, 53-67.	1.9	16
362	Targeting the RAS pathway by mitogen-activated protein kinase inhibitors. Swiss Medical Weekly, 2015, 145, w14207.	0.8	16
363	Significance of anti-inflammatory effects of PPARÂ agonists?. Gut, 2005, 55, 1067-1069.	6.1	15
364	A new organotypic model to study cell interactions in the intestinal mucosa. European Journal of Gastroenterology and Hepatology, 2006, 18, 901-909.	0.8	15
365	Gene expression profiles of mucosal fibroblasts from strictured and nonstrictured areas of patients with Crohn's disease. Inflammatory Bowel Diseases, 2009, 15, 212-223.	0.9	15
366	Coping is excellent in Swiss Children with inflammatory bowel disease: Results from the Swiss IBD cohort study. Journal of Crohn's and Colitis, 2014, 8, 409-420.	0.6	15
367	The appearance of joint manifestations in the Swiss inflammatory bowel disease cohort. PLoS ONE, 2019, 14, e0211554.	1.1	15
368	Clinical Relevance of Anti-TNF Antibody Trough Levels and Anti-Drug Antibodies in Treating Inflammatory Bowel Disease Patients. Inflammatory Intestinal Diseases, 2021, 6, 1-10.	0.8	15
369	Protein tyrosine phosphatase non-receptor type 22 modulates colitis in a microbiota-dependent manner. Journal of Clinical Investigation, 2019, 129, 2527-2541.	3.9	15
370	Inhibition of integrin αvβ6 sparks T-cell antitumor response and enhances immune checkpoint blockade therapy in colorectal cancer. , 2022, 10, e003465.		15
371	Coombs-positive autoimmune hemolytic anemia in Crohn??s disease. European Journal of Gastroenterology and Hepatology, 2005, 17, 661-666.	0.8	14
372	Crohn's Disease of the Esophagus: Treatment of an Esophagobronchial Fistula with the Novel Liquid Embolic Polymer "Onyx― Zeitschrift Fur Gastroenterologie, 2006, 44, 599-602.	0.2	14
373	Patients' perceptions on the impact of coffee consumption in inflammatory bowel disease: friend or foe? – a patient survey. Nutrition Journal, 2015, 14, 78.	1.5	14
374	Alicaforsen, an Antisense Inhibitor of Intercellular Adhesion Molecule-1, in the Treatment for Left-Sided Ulcerative Colitis and Ulcerative Proctitis. Digestive Diseases, 2018, 36, 123-129.	0.8	14
375	The Vampire Study: Significant elevation of faecal calprotectin in healthy volunteers after 300 ml blood ingestion mimicking upper gastrointestinal bleeding. United European Gastroenterology Journal, 2018, 6, 1007-1014.	1.6	14
376	Protein Tyrosine Phosphatase Non-Receptor Type 2 Function in Dendritic Cells Is Crucial to Maintain Tissue Tolerance. Frontiers in Immunology, 2020, 11, 1856.	2.2	14
377	Novel Strategies to Prevent Total Parenteral Nutritionâ€Induced Gut and Liver Inflammation, and Adverse Metabolic Outcomes. Molecular Nutrition and Food Research, 2021, 65, e1901270.	1.5	14
378	Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn's Disease. Inflammatory Bowel Diseases, 2021, 27, 106-122.	0.9	14

#	Article	IF	CITATIONS
379	HDL3-retroendocytosis in cultured small intestinal crypt cells: a novel mechanism of cholesterol efflux. Biochimica Et Biophysica Acta - Molecular Cell Research, 1991, 1095, 30-38.	1.9	13
380	Regulation of Cholesterol Metabolism and Low-Density Lipoprotein Binding in Human Intestinal Caco-2 Cells. Digestion, 1992, 51, 10-17.	1.2	13
381	The importance of gut microbiota in mediating the effect of NOD2 defects in inflammatory bowel disease. Gut, 2010, 59, 153-154.	6.1	13
382	The Innate Immune System: A Trigger for Many Chronic Inflammatory Intestinal Diseases. Inflammatory Intestinal Diseases, 2016, 1, 70-77.	0.8	13
383	Risk factors for complications in patients with ulcerative colitis. United European Gastroenterology Journal, 2016, 4, 281-287.	1.6	13
384	The Efficacy and Safety of Golimumab as Third- or Fourth-Line Anti-TNF Therapy in Patients with Refractory Crohn's Disease: A Case Series. Inflammatory Intestinal Diseases, 2017, 2, 131-138.	0.8	13
385	Transplantation of Human Intestine Into the Mouse: A Novel Platform for Study of Inflammatory Enterocutaneous Fistulas. Journal of Crohn's and Colitis, 2019, 13, 798-806.	0.6	13
386	A Novel OGR1 (GPR68) Inhibitor Attenuates Inflammation in Murine Models of Colitis. Inflammatory Intestinal Diseases, 2021, 6, 140-153.	0.8	13
387	Systemic Jak1 activation provokes hepatic inflammation and imbalanced FGF23 production and cleavage. FASEB Journal, 2021, 35, e21302.	0.2	13
388	(GT)n Dinucleotide repeat polymorphism of haem oxygenase-1 promotor region is not associated with inflammatory bowel disease risk or disease course. Clinical and Experimental Immunology, 2008, 153, 81-85.	1.1	12
389	Drug-induced Erythema Nodosum After the Administration of Certolizumab in Crohn's Disease. Inflammatory Bowel Diseases, 2013, 19, E4-E6.	0.9	12
390	New Therapeutic Avenues for Treatment of Fibrosis: Can We Learn from Other Diseases?. Digestive Diseases, 2014, 32, 39-49.	0.8	12
391	Therapeutic Drug Monitoring to Guide Clinical Decision Making in Inflammatory Bowel Disease Patients with Loss of Response to Anti-TNF: A Delphi Technique-Based Consensus. Digestion, 2020, 101, 683-691.	1.2	12
392	Reconsidering the "protective―hypothesis of <i>Helicobacter pylori</i> infection in eosinophilic esophagitis. Annals of the New York Academy of Sciences, 2020, 1481, 59-71.	1.8	12
393	Evaluating key characteristics of ideal colorectal cancer screening modalities: the microsimulation approach. Gastrointestinal Endoscopy, 2021, 94, 379-390.e7.	0.5	12
394	The Intestinal Barrier—Shielding the Body from Nano- and Microparticles in Our Diet. Metabolites, 2022, 12, 223.	1.3	12
395	Immune-non Immune Networks in Intestinal Inflammation. Current Drug Targets, 2008, 9, 388-394.	1.0	11
396	Differential afferent sensitivity to mucosal lipopolysaccharide from <i>Salmonella typhimurium</i> and <i>Escherichia coli</i> in the rat jejunum. Neurogastroenterology and Motility, 2009, 21, 1335.	1.6	11

#	Article	IF	CITATIONS
397	Pathogenesis of Strictures in Ulcerative Colitis: A Field to Explore. Digestion, 2011, 84, 10-11.	1.2	11
398	The role for protein tyrosine phosphatase nonreceptor type 2 in regulating autophagosome formation. Annals of the New York Academy of Sciences, 2012, 1257, 93-102.	1.8	11
399	Is There Still a Role for Thiopurines in Crohn's Disease?. Gastroenterology, 2013, 145, 714-716.	0.6	11
400	Cell-wall deficient L. monocytogenes L-forms feature abrogated pathogenicity. Frontiers in Cellular and Infection Microbiology, 2014, 4, 60.	1.8	11
401	Prevalence and Risk Factors for Therapy Escalation in Ulcerative Colitis in the Swiss IBD Cohort Study. Inflammatory Bowel Diseases, 2015, 21, 1.	0.9	11
402	Oral administration of dextran sodium sulphate induces a caecumâ€localized colitis in rabbits. International Journal of Experimental Pathology, 2015, 96, 151-162.	0.6	11
403	Helminth therapy for organic diseases?. Translational Research, 2015, 166, 586-601.	2.2	11
404	Assessment of Inflammatory Bowel Disease Patient's Needs and Problems from a Nursing Perspective. Digestion, 2015, 91, 128-141.	1.2	11
405	Deficiency of Protein Tyrosine Phosphatase Non-Receptor Type 2 in Intestinal Epithelial Cells Has No Appreciable Impact on Dextran Sulphate Sodium Colitis Severity But Promotes Wound Healing. Digestion, 2016, 93, 249-259.	1.2	11
406	Contribution of CD3+CD8- and CD3+CD8+ T Cells to TNF- <i>α</i> Overexpression in Crohn Disease–Associated Perianal Fistulas and Induction of Epithelial-Mesenchymal Transition in HT-29 Cells. Inflammatory Bowel Diseases, 2021, 27, 538-549.	0.9	11
407	Abdominal pain in patients with inflammatory bowel disease: association with single-nucleotide polymorphisms prevalent in irritable bowel syndrome and clinical management. BMC Gastroenterology, 2021, 21, 53.	0.8	11
408	Role of soluble factors and three-dimensional culture inin vitrodifferentiation of intestinal macrophages. World Journal of Gastroenterology, 2007, 13, 1032.	1.4	11
409	HDL3-mediated cholesterol efflux from cultured enterocytes: The role of apoproteins A-I and A-II. Lipids, 1994, 29, 735-745.	0.7	10
410	Interferon gamma downregulates IL-8 production in primary human colonic epithelial cells without induction of apoptosis. International Journal of Colorectal Disease, 2004, 19, 421-9.	1.0	10
411	Lack of transketolase-like (TKTL) 1 aggravates murine experimental colitis. American Journal of Physiology - Renal Physiology, 2011, 300, G598-G607.	1.6	10
412	Environmental Factors and Their Impact on the Intestinal Microbiota: A Role for Human Disease?. Digestive Diseases, 2012, 30, 20-27.	0.8	10
413	A Shift From Oral to Intravenous Iron Supplementation Therapy Is Observed Over Time in a Large Swiss Cohort of Patients With Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2013, 19, 840-846.	0.9	10
414	Steroid Use in Crohn's Disease. Drugs, 2014, 74, 313-324.	4.9	10

#	Article	IF	CITATIONS
415	Risk Factors for the Development of Fistulae and Stenoses in Crohn Disease Patients in the Swiss Inflammatory Bowel Disease Cohort. Inflammatory Intestinal Diseases, 2016, 1, 172-181.	0.8	10
416	The Clinical Relevance of the IBD-Associated Variation within the Risk Gene Locus Encoding Protein Tyrosine Phosphatase Non-Receptor Type 2 in Patients of the Swiss IBD Cohort. Digestion, 2016, 93, 182-192.	1.2	10
417	Anti-Cytokine Strategies beyond Anti-Tumour Necrosis Factor-α Therapy: Pathophysiology and Clinical Implications. Digestive Diseases, 2017, 35, 5-12.	0.8	10
418	Alicaforsen in the treatment of pouchitis. Immunotherapy, 2017, 9, 1143-1152.	1.0	10
419	New Therapeutic Approach for Intestinal Fibrosis Through Inhibition of pH-Sensing Receptor GPR4. Inflammatory Bowel Diseases, 2022, 28, 109-125.	0.9	10
420	Regulation of the Expression of Chaperone gp96 in Macrophages and Dendritic Cells. PLoS ONE, 2013, 8, e76350.	1.1	10
421	Functional expression of the interleukin-11 receptor alpha-chain in normal colonic epithelium and colon cancer. International Journal of Colorectal Disease, 2006, 21, 573-581.	1.0	9
422	Infliximab for Crohn's disease in the Swiss IBD Cohort Study. European Journal of Gastroenterology and Hepatology, 2010, 22, 1352-1357.	0.8	9
423	Appropriateness of therapy for fistulizing Crohn's disease: findings from a national inflammatory bowel disease cohort. Alimentary Pharmacology and Therapeutics, 2010, 32, 1007-1016.	1.9	9
424	Knock-Out of β-Glucosidase 2 Has No Influence on Dextran Sulfate Sodium-Induced Colitis. Digestion, 2011, 84, 156-167.	1.2	9
425	Effects of Retinoids in Mouse Models of Colitis. Inflammatory Bowel Diseases, 2013, 19, 2356-2365.	0.9	9
426	Donor Nucleotide-Binding Oligomerization–Containing Protein 2 (NOD2) Single Nucleotide Polymorphism 13 Is Associated with Septic Shock after Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, 1399-1404.	2.0	9
427	Celiac Disease is Misdiagnosed Based on Serology Only in a Substantial Proportion of Patients. Journal of Clinical Gastroenterology, 2018, 52, 25-29.	1.1	9
428	A multicentre prospective cohort study assessing the effectiveness of budesonide MMX® (Cortiment® ^{MMX®}) for active, mildâ€ŧoâ€moderate ulcerative colitis. United European Gastroenterology Journal, 2019, 7, 1171-1182.	1.6	9
429	Iron Prevents Hypoxia-Associated Inflammation Through the Regulation of Nuclear Factor-κB in the Intestinal Epithelium. Cellular and Molecular Gastroenterology and Hepatology, 2019, 7, 339-355.	2.3	9
430	A single nucleotide polymorphism in the gene for GPR183 increases its surface expression on blood lymphocytes of patients with inflammatory bowel disease. British Journal of Pharmacology, 2021, 178, 3157-3175.	2.7	9
431	pH-Sensing G Protein-Coupled Receptor OGR1 (GPR68) Expression and Activation Increases in Intestinal Inflammation and Fibrosis. International Journal of Molecular Sciences, 2022, 23, 1419.	1.8	9
432	IOIBD Recommendations for Clinical Trials in Ulcerative Proctitis: The PROCTRIAL Consensus. Clinical Gastroenterology and Hepatology, 2022, 20, 2619-2627.e1.	2.4	9

#	Article	IF	CITATIONS
433	Lipid emulsion rich in n–3 polyunsaturated fatty acids elicits a pro-resolution lipid mediator profile in mouse tissues and in human immune cells. American Journal of Clinical Nutrition, 2022, 116, 786-797.	2.2	9
434	Improved separation of radioactively labelled cellular phospholipids by high-performance liquid chromatography. Biomedical Applications, 1994, 656, 73-76.	1.7	8
435	Mevalonate is essential for growth of porcine and human vascular smooth muscle cells in vitro. Basic Research in Cardiology, 1995, 90, 443-450.	2.5	8
436	Can NOD2/CARD15 mutations predict intestinal graft-versus-host disease and aid our understanding of Crohn's disease?. Nature Reviews Gastroenterology & Hepatology, 2004, 1, 62-63.	1.7	8
437	NAT1 Genotypes Do not Predict Response to Mesalamine in Patients with Ulcerative Colitis. Zeitschrift Fur Gastroenterologie, 2008, 46, 259-265.	0.2	8
438	Lessons from a transplant patient with diarrhea, cryptosporidial infection, and possible mycophenolate mofetilâ€associated colitis. Transplant Infectious Disease, 2011, 13, 416-418.	0.7	8
439	Analysis of TNF-antagonist switch over time and associated risk factors in the Swiss Inflammatory Bowel Disease Cohort. Scandinavian Journal of Gastroenterology, 2014, 49, 1207-1218.	0.6	8
440	VAlidation of an 8-item-questionnaire predictive for a positive caLprotectin tEst and Real-life implemenTation in primary care to reduce diagnostic delay in inflammatory bowel disease (ALERT): protocol for a prospective diagnostic study. BMJ Open, 2015, 5, e007306-e007306.	0.8	8
441	The Impact of Cold Spells on the Incidence of Infectious Gastroenteritis and Relapse Rates of Inflammatory Bowel Disease: A Retrospective Controlled Observational Study. Inflammatory Intestinal Diseases, 2017, 2, 124-130.	0.8	8
442	Differences in Outcomes Reported by Patients WithÂInflammatory Bowel Diseases vs Their HealthÂCareÂProfessionals. Clinical Gastroenterology and Hepatology, 2019, 17, 2050-2059.e1.	2.4	8
443	Improved treatment outcome and lower skin toxicity with intensity-modulated radiotherapy vs. 3D conventional radiotherapy in anal cancer. Strahlentherapie Und Onkologie, 2020, 196, 356-367.	1.0	8
444	Choice of Lipid Emulsion Determines Inflammation of the Gut‣iver Axis, Incretin Profile, and Insulin Signaling in a Murine Model of Total Parenteral Nutrition. Molecular Nutrition and Food Research, 2021, 65, e2000412.	1.5	8
445	Treatment of Pouchitis with Dehydroepiandrosterone (DHEA) - a Case Report. Zeitschrift Fur Gastroenterologie, 2003, 41, 1087-1090.	0.2	7
446	(E)-metanicotine hemigalactarate (TC-2403-12) inhibits IL-8 production in cells of the inflamed mucosa. International Journal of Colorectal Disease, 2007, 22, 303-312.	1.0	7
447	Primary human colonic epithelial cells are transiently protected from anoikis by a Src-dependent mechanism. Biochemical and Biophysical Research Communications, 2009, 390, 908-914.	1.0	7
448	New Onset, Aggravation and Recurrence of Crohn's Disease upon Treatment with Three Different Tumor Necrosis Factor Inhibitors. Case Reports in Gastroenterology, 2015, 9, 106-112.	0.3	7
449	Genotype-Phenotype Associations of the CD-Associated Single Nucleotide Polymorphism within the Gene Locus Encoding Protein Tyrosine Phosphatase Non-Receptor Type 22 in Patients of the Swiss IBD Cohort. PLoS ONE, 2016, 11, e0160215.	1.1	7
450	Effectiveness of budesonide MMX (Cortiment) for the treatment of mild-to-moderate active ulcerative colitis: study protocol for a prospective multicentre observational cohort study. BMJ Open Gastroenterology, 2016, 3, e000092.	1.1	7

#	Article	IF	CITATIONS
451	Protocol for a prospective, controlled, observational study to evaluate the influence of hypoxia on healthy volunteers and patients with inflammatory bowel disease: the Altitude IBD Study. BMJ Open, 2017, 7, e013477.	0.8	7
452	Gp96 deficiency affects TLR4 functionality and impairs ERK and p38 phosphorylation. PLoS ONE, 2018, 13, e0193003.	1.1	7
453	Genetic risk factors predict disease progression in Crohn's disease patients of the Swiss inflammatory bowel disease cohort. Therapeutic Advances in Gastroenterology, 2020, 13, 175628482095925.	1.4	7
454	Treatment algorithm for moderate to severe ulcerative colitis. Swiss Medical Weekly, 2011, 141, w13235.	0.8	7
455	Morphology of CaCo-2 cells varies in different cell batches. In Vitro Cellular and Developmental Biology - Animal, 1994, 30, 289-291.	0.7	6
456	Sonographische Kontrolle von Magensonden bei Intensivpatienten. Intensivmedizin Und Notfallmedizin, 2003, 40, 693-697.	0.2	6
457	Serum antibodies to EpCAM in healthy donors but not ulcerative colitis patients. Cancer Immunology, Immunotherapy, 2006, 55, 528-537.	2.0	6
458	Dying in Yoghurt: The Number of Living Bacteria in Probiotic Yoghurt Decreases under Exposure to Room Temperature. Digestion, 2011, 83, 13-17.	1.2	6
459	The History and Philosophy of Inflammatory Bowel Disease. Digestive Diseases, 2013, 31, 270-277.	0.8	6
460	Making a Case for Case Reports: The ECCO-CONFER Viewpoint on Investigating Rare Events in a Medical World Reigned by Group-comparative Statistics. Journal of Crohn's and Colitis, 2017, 11, 256-257.	0.6	6
461	Rectal Insulin Instillation Inhibits Inflammation and Tumor Development in Chemically Induced Colitis. Journal of Crohn's and Colitis, 2018, 12, 1459-1474.	0.6	6
462	Effects of anti-TNF therapy and immunomodulators on anxiety and depressive symptoms in patients with inflammatory bowel disease: a 5-year analysis. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482110337.	1.4	6
463	Modulation of the Mucosa-Associated Microbiome Linked to the PTPN2 Risk Gene in Patients with Primary Sclerosing Cholangitis and Ulcerative Colitis. Microorganisms, 2021, 9, 1752.	1.6	6
464	Volcano-like intermittent bleeding activity for seven years from an arterio-enteric fistula on a kidney graft site after pancreas-kidney transplantation: a case report. Journal of Medical Case Reports, 2010, 4, 357.	0.4	5
465	Variants in Autophagy Genes Affect Susceptibility to Both Crohn's Disease and Helicobacter pylori Infection. Gastroenterology, 2012, 142, 1060-1063.	0.6	5
466	Impaired removal of Vβ8+lymphocytes aggravates colitis in mice deficient for B cell lymphoma-2-interacting mediator of cell death (Bim). Clinical and Experimental Immunology, 2013, 173, 493-501.	1.1	5
467	Gastroresistant oral peptide for fluorescence imaging of colonic inflammation. Journal of Controlled Release, 2017, 262, 118-126.	4.8	5
468	Prevalence and Determinants of Job Stress in Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2017, 23, 310-317.	0.9	5

#	Article	IF	CITATIONS
469	Low serum zinc levels predict presence of depression symptoms, but not overall disease outcome, regardless of ATG16L1 genotype in Crohn's disease patients. Therapeutic Advances in Gastroenterology, 2018, 11, 1756283X1875771.	1.4	5
470	Association of IBD specific treatment and prevalence of pain in the Swiss IBD cohort study. PLoS ONE, 2019, 14, e0215738.	1.1	5
471	Actual Anti-TNF Trough Levels Relate to Serum IL-10 in Drug-Responding Patients With Crohn's Disease. Inflammatory Bowel Diseases, 2019, 25, 1357-1366.	0.9	5
472	Feasibility of an 8â€item questionnaire for early diagnosis of inflammatory bowel disease in primary care. Journal of Evaluation in Clinical Practice, 2019, 25, 155-162.	0.9	5
473	Varicella Zoster Virus in Inflammatory Bowel Disease Patients: What Every Gastroenterologist Should Know. Journal of Crohn's and Colitis, 2021, 15, 316-325.	0.6	5
474	Effectiveness of golimumab in patients with ulcerative colitis: results of a real-life study in Switzerland. Therapeutic Advances in Gastroenterology, 2022, 15, 175628482210741.	1.4	5
475	Gut microbiome and circulating bacterial DNA ("blood microbiomeâ€) in a mouse model of total parenteral nutrition: Evidence of two distinct separate microbiotic compartments. Clinical Nutrition ESPEN, 2022, 49, 278-288.	0.5	5
476	Intracellular Transport of High-Density Lipoprotein 3 in Intestinal Epithelial Cells (Caco-2) Is Tubulin Associated. Digestion, 2000, 61, 47-58.	1.2	4
477	MIP-3α Expression in Macrophages Is NOD Dependent. Digestion, 2012, 85, 192-201.	1.2	4
478	Addressing current treatment challenges in Crohn's disease in real life: A physician's survey. Digestive and Liver Disease, 2014, 46, 1066-1071.	0.4	4
479	Serum anti-glycan-antibodies in relatives of patients with inflammatory bowel disease. PLoS ONE, 2018, 13, e0194222.	1.1	4
480	Lower Risk of B1-to-pB3-Stage Migration in Crohn's Disease Upon Immunosuppressive and Anti-TNF Treatment in the Swiss IBD Cohort Study. Digestive Diseases and Sciences, 2020, 65, 2654-2663.	1.1	4
481	Solute Carrier Family 12 Member 2 as a Proteomic and Histological Biomarker of Dysplasia and Neoplasia in Ulcerative Colitis. Journal of Crohn's and Colitis, 2021, 15, 287-298.	0.6	4
482	Diet and Inflammatory Bowel Disease: What Quality Standards Should Be Applied in Clinical and Laboratory Studies?. Molecular Nutrition and Food Research, 2021, 65, e2000514.	1.5	4
483	Combination of Vedolizumab With Tacrolimus Is More Efficient Than Vedolizumab Alone in the Treatment of Experimental Colitis. Inflammatory Bowel Diseases, 2021, 27, 1986-1998.	0.9	4
484	The impact of colectomy on the course of extraintestinal manifestations in Swiss inflammatory bowel disease cohort study patients. United European Gastroenterology Journal, 2021, 9, 773-780.	1.6	4
485	NOD2/CARD15 Variants of Donor and Recipient as Critical Risk Factors for the Development of Bronchiolitis Obliterans Syndrome after Allogeneic Stem Cell Transplantation Blood, 2005, 106, 144-144.	0.6	4
486	Su1261 Expression of Interleukins 22 and 33, Matrix Metalloproteinases 9 and 13, Mast Cell Markers and Hypoxia-Inducible Factor 1α in Crohn's Disease Associated Fistulae. Gastroenterology, 2013, 144, S-441-S-442.	0.6	3

#	Article	IF	CITATIONS
487	Integrating Imaging into Clinical Practice in Inflammatory Bowel Disease. Digestive Diseases, 2015, 33, 37-43.	0.8	3
488	The perspective of celiac disease patients on emerging treatment options and non-celiac gluten sensitivity. Digestive and Liver Disease, 2017, 49, 268-272.	0.4	3
489	The long and winding road: from genetic risk factors to the understanding of disease-pathogenesis in Crohn's disease. Genes and Immunity, 2019, 20, 607-608.	2.2	3
490	Can the CalproQuest predict a positive Calprotectin test? A prospective diagnostic study. PLoS ONE, 2019, 14, e0224961.	1.1	3
491	The Influence of Breastfeeding, Cesarean Section, Pet Animals, and Urbanization on the Development of Inflammatory Bowel Disease: Data from the Swiss IBD Cohort Study. Inflammatory Intestinal Diseases, 2020, 5, 170-179.	0.8	3
492	Macrophages Compensate for Loss of Protein Tyrosine Phosphatase N2 in Dendritic Cells to Protect from Elevated Colitis. International Journal of Molecular Sciences, 2021, 22, 6820.	1.8	3
493	Late onset primary oxalosis type I. European Journal of Gastroenterology and Hepatology, 1998, 10, 809-812.	0.8	2
494	â€~Red Alert' or Not? – Do We Give Our Inflammatory Bowel Disease Patients the Right Dietary Recommendations?. Digestion, 2011, 84, 236-237.	1.2	2
495	A distinct pattern of disease-associated single nucleotide polymorphisms in IBD risk genes in a family with Crohn's disease. European Journal of Gastroenterology and Hepatology, 2014, 26, 803-806.	0.8	2
496	Exogenous Heat Shock Protein gp96 Ameliorates CD4+CD62L+ T-Cell–mediated Transfer Colitis. Inflammatory Bowel Diseases, 2014, 20, 1933-1941.	0.9	2
497	Fistulising disease—a problem shared is a problem halved?. Nature Reviews Gastroenterology and Hepatology, 2014, 11, 581-583.	8.2	2
498	Editorial: is thalidomide a good option for patients with refractory Crohn's disease?. Alimentary Pharmacology and Therapeutics, 2015, 41, 785-786.	1.9	2
499	Immune Cells: Monocytes and Macrophages. , 2017, , 119-122.		2
500	Disease Progression and Outcomes of Pregnancies in Women With Eosinophilic Esophagitis. Clinical Gastroenterology and Hepatology, 2020, 18, 2456-2462.	2.4	2
501	Effect of distance to specialist care for the diagnosis and disease outcome of inflammatory bowel disease in the Swiss inflammatory bowel disease cohort study. Therapeutic Advances in Gastroenterology, 2020, 13, 175628481989521.	1.4	2
502	Medikamentöse Therapie der Colitis ulcerosa und Pouchitis. , 2020, , 285-303.		2
503	Anthocyanins and anthocyanidins are poor inhibitors of CYP2D6. Methods and Findings in Experimental and Clinical Pharmacology, 2009, 31, 3.	0.8	2
504	Induction of toll-like receptor 2 in human intestinal myofibroblasts by interferon gamma. Gastroenterology, 2000, 118, A791.	0.6	1

#	Article	IF	CITATIONS
505	Genomics and inductive reasoning: Revolution, renaissance, or rhetoric?. Genetics in Medicine, 2003, 5, 476-478.	1.1	1
506	299: The role of SNPs within receptors of innate immunity in outcome following allogeneic stem cell transplantation. Biology of Blood and Marrow Transplantation, 2007, 13, 108-109.	2.0	1
507	Preface. Digestive Diseases, 2009, 27, 205-205.	0.8	1
508	Recognition of commensal microbes: if innate responses are NOD in balance. Expert Review of Clinical Immunology, 2010, 6, 205-210.	1.3	1
509	Knock-out of BCL-2 Interacting Mediator of Cell Death (BIM) Decreases Apoptosis in Intestinal Epithelial Cells and Ameliorates Acute DSS Colitis. Gastroenterology, 2011, 140, S-648.	0.6	1
510	Prebiotics and Probiotics in Ulcerative Colitis: Where Do We Stand?. Digestion, 2011, 84, 126-127.	1.2	1
511	Mast cells and the cyclooxygenase pathway mediate colonic afferent nerve sensitization in a murine colitis model. Autonomic Neuroscience: Basic and Clinical, 2013, 174, 47-53.	1.4	1
512	Editorial: how to interpret risks and prediction of complications in Crohn's disease – can our patients interpret them?. Alimentary Pharmacology and Therapeutics, 2016, 43, 651-652.	1.9	1
513	Anthocyane, Heidelbeeren und Curcuma: Wirksame Therapeutika bei Darmentzündungen?. Schweizerische Zeitschrift Für GanzheitsMedizin, 2017, 29, 137-140.	0.0	1
514	Eribulin Does Not Prevent Epithelial-to-Mesenchymal Transition in HT-29 Intestinal Epithelial Cells. Inflammatory Intestinal Diseases, 2017, 2, 211-218.	0.8	1
515	Challenges of Translation of Anti-Fibrotic Therapies into Clinical Practice in IBD. , 2018, , 295-305.		1
516	Responses to the Letter to the Editor by Brusciano et al Neurogastroenterology and Motility, 2020, 32, e13981.	1.6	1
517	Perianal fistulodesis – A pilot study of a novel minimally invasive surgical and medical approach for closure of perianal fistulae. World Journal of Gastrointestinal Surgery, 2021, 13, 187-197.	0.8	1
518	Higher educational level in patients with eosinophilic esophagitis: a comparative analysis. Ecological Management and Restoration, 2021, 34, .	0.2	1
519	Nutrition—or Lack Thereof—As a Source of Gut Inflammation: Evidence from Basic Science and Clinical Studies. Molecular Nutrition and Food Research, 2021, 65, e2001086.	1.5	1
520	The Role of the Chaperone Grp94/Gp96 in the Intestinal Barrier and Innate Immune Functions. Current Immunology Reviews, 2017, 13, .	1.2	1
521	MMP9 expression in intestinal fistula from patients with fistulizing CD and from human xenograft mouse model. Tissue Barriers, 2021, , 1994350.	1.6	1
522	Inflammatory bowel disease in sub-Saharan Africa: a protocol of a prospective registry with a nested case–control study. BMJ Open, 2020, 10, e039456.	0.8	1

#	Article	IF	CITATIONS
523	Inflammatory Bowel Disease in Travelers. Gastroenterology and Hepatology, 2018, 14, 377-379.	0.2	1
524	Intestinal epithelial cells induce selection of a small subpopulation of monocytes during coculture. Gastroenterology, 2000, 118, A1371.	0.6	0
525	Secretion andexpression of IL-8 in IFNΓ stimulated human colonic epithelial cells depends on cell differentiation. Gastroenterology, 2000, 118, A603.	0.6	Ο
526	Subtractive screening reveals increased expression of cathepsin D in intestinal macrophages from inflammatory bowel disease mucosa. Gastroenterology, 2000, 118, A345.	0.6	0
527	Platelet activation in patients with inflammatory bowel disease. Gastroenterology, 2000, 118, A1359.	0.6	Ο
528	Intestinal graft versus host disease detected and monitored by ultrasound. Gastroenterology, 2000, 118, A1411.	0.6	0
529	Analysis of a novel polymorphism in the MCP-1 gene: Influence on mucosal MCP-1 expression and disease activity in IBD. Gastroenterology, 2000, 118, A799.	0.6	0
530	A three dimensional organotypic model for the study of cell interaction in the intestinal mucosa. Gastroenterology, 2000, 118, A362.	0.6	0
531	Bile salt induced apoptosis in colon cancer cell lines: Mechanisms and differences to primary colon epithelial cells. Gastroenterology, 2000, 118, A553.	0.6	Ο
532	Systemic caspase-inhibitors severely aggravate colitis in rodent models of colitis. Gastroenterology, 2000, 118, A1135.	0.6	0
533	Correlation between nickel allergy towards dentures and Crohn's disease: A case report. Gastroenterology, 2000, 118, A1135.	0.6	Ο
534	Downregulation of IL-1beta RNA in monocytes/macrophages during coculture with intestinal epithelial cells. Gastroenterology, 2000, 118, A1137.	0.6	0
535	Bile acid mediated apoptosis in human colon cancer cell lines is not mediated via the CD95/Fas/Apo-1 pathway. Gastroenterology, 2000, 118, A1140.	0.6	0
536	IFN-b variously regulates IL-8 secretion in human colonic myofibroblasts and in primary human colonic epithelial cells. Gastroenterology, 2000, 118, A109.	0.6	0
537	The expression of fibronectin splcing-forms ED-A and ED-B is reduced in IBD mucosa. Gastroenterology, 2003, 124, A331.	0.6	Ο
538	Regulation of the adipocyte specific protein APM-1 in inflammatory bowel disease. Gastroenterology, 2003, 124, A325.	0.6	0
539	The glycoprotein (gp) 96 is absent in intestinal macrophages from patients with inflammatory bowel disease (IBD). Gastroenterology, 2003, 124, A497.	0.6	0
540	The migratory potential of Crohn's disease myofibroblasts differs significantly between inflamed mucosa, strictures and fistulae. Gastroenterology, 2003, 124, A329.	0.6	0

#	Article	IF	CITATIONS
541	Identification and quantification of soluble TNF receptors I and II in serum of IBD patients. Gastroenterology, 2003, 124, A336.	0.6	0
542	Cathepsin D contributes to mucosal damage in inflammatory bowel disease. Gastroenterology, 2003, 124, A325.	0.6	0
543	Specific differences in the cytokine/receptor expression pattern of Crohn's disease mast cells and mast cells from normal mucosa. Gastroenterology, 2003, 124, A335-A336.	0.6	Ο
544	Multi-site therapeutic modalities for inflammatory bowel diseases — mechanisms of action. , 2003, , 523-551.		0
545	A Janus-Headed Polyp: Adenoma and Carcinoma with a Single Stalk. Endoscopy, 2005, 37, 96-96.	1.0	0
546	Epithelial Response. Inflammatory Bowel Diseases, 2006, 12, S6-S7.	0.9	0
547	NOD2/CARD15 Mutations Associate With Transplant-related Mortality and GvHD in HLA-Identical Sibling Transplants. Inflammatory Bowel Diseases, 2006, 12, S19.	0.9	0
548	Is Inflammatory Bowel Disease More Severe when It Appears at Younger Ages?. Digestion, 2010, 81, 235-236.	1.2	0
549	S1211 Extraintestinal Manifestations in Inflammatory Bowel Disease: Frequency and Associated Risk Factors in the Nationwide Swiss IBD Cohort Study (SIBDCS). Gastroenterology, 2010, 138, S-205.	0.6	0
550	Transcription Factor NRF2 and Its Target Genes Are Differently Regulated in Acute and Chronic Colitis. Gastroenterology, 2011, 140, S-636.	0.6	0
551	Overexpression of Receptors for Insulin and Epidermal Growth Factor in Dysplastic Inflamed Colonic Mucosa Correlates With Increased Cancer Risk in Patients With Ulcerative Colitis. Gastroenterology, 2011, 140, S-350.	0.6	0
552	Oxidative Stress and Deletion of Transketolase-Like (TKTL) 1 in Murine Experimental Colitis. Gastroenterology, 2011, 140, S-649.	0.6	0
553	Transforming Growth Factor Beta and Interleukin-13 Synergize in the Pathogenesis of Crohn's Disease Associated Intestinal Fistulae. Gastroenterology, 2011, 140, S-285.	0.6	0
554	The Lipids Sphingomyelin and Phosphatidylcholine Contrarily Affect the Induction of Apoptosis in Human Intestinal Epithelial Cells. Gastroenterology, 2011, 140, S-859-S-860.	0.6	0
555	Anti-Inflammatory Properties of High Density Lipoprotein (HDL) on Intestinal Epithelial Cells. Gastroenterology, 2011, 140, S-838.	0.6	0
556	Role of pH Receptors in Murine Experimental Colitis. Gastroenterology, 2011, 140, S-516.	0.6	0
557	A New Animal Model of Intestinal Fibrosis. Gastroenterology, 2011, 140, S-657.	0.6	0
558	Protein Tyrosine Phosphatase Non-Receptor Type 2 is a Regulator of Authophagosome Function. Gastroenterology, 2011, 140, S-172.	0.6	0

#	Article	IF	CITATIONS
559	Loss of Heat Shock Protein gp96 Does Not Impair Toll Like Receptor Signaling In Vitro. Gastroenterology, 2011, 140, S-332.	0.6	0
560	Protein Tyrosine Phosphatase Non-Receptor Type 2 Regulates NLRP3 Inflammasome Activation. Gastroenterology, 2011, 140, S-633.	0.6	0
561	Comparison of Protein Expression Profiles in Inflammatory Bowel Disease and Concomitant Cutaneous Manifestations on Tissue Microarrays. Gastroenterology, 2011, 140, S-427.	0.6	Ο
562	The Crohn's Disease Associated Variant of the Protein Tyrosine Phosphatase Non-Receptor Type 2 Gene Affects Cellular Responses to Invading Listeria Monocytogenes. Gastroenterology, 2011, 140, S-496.	0.6	0
563	Systematic Assessment of Items Influencing Crohn's Disease Patient's Preferences in Selecting an Anti-TNF Agent (Choose TNF Trial). Gastroenterology, 2011, 140, S-593.	0.6	0
564	The Crohn's Disease Candidate Gene, Protein Tyrosine Phosphatase Non-Receptor Type 2, Regulates Muramyldipetide-Induced NOD2-Dependent Effects in Human Monocytes and Fibroblasts. Gastroenterology, 2011, 140, S-487.	0.6	0
565	The FC Fragment of Infliximab Inhibits Its Activity in Intestinal Fibroblasts and Monocytes via High Affinity IgG Receptor CD64. Gastroenterology, 2011, 140, S-837.	0.6	0
566	Expression of the G Protein-Coupled Receptor 68 is Increased by TNF-Mediated Inflammatory Signalling. Gastroenterology, 2011, 140, S-837-S-838.	0.6	0
567	Is This Stricture Inflammatory?. Digestion, 2011, 83, 261-262.	1.2	0
568	Preface. Digestion, 2012, 86, IV-IV.	1.2	0
569	Dealing with Our 'In-Vironment': New Aspects of Inflammatory Bowel Disease Pathogenesis and Therapy. Digestive Diseases, 2012, 30, 1-1.	0.8	0
570	Intensified Anti-TNF-Alpha Therapy and Bacterial-DNA Translocation in Patients With Mutated NOD2/ATG16L1-Combined Genotypes. Inflammatory Bowel Diseases, 2012, 18, S60.	0.9	0
571	Mo1976 Knock-out of BCL-2 Interacting Mediator of Cell Death (Bim) Aggravates Chronic DSS-Induced Colitis. Gastroenterology, 2012, 142, S-712.	0.6	0
572	Serum REG3alpha and C-Reactive Protein Levels in Crohn's Disease Patients Undergoing Immunoablation and Autologous Hemopoetic Stem Cell Transplantation in the ASTIC Trial. Digestion, 2015, 92, 83-89.	1.2	0
573	828 Prolonged Regression of Ileocolonic Crohn's Disease Following Autologous Haemopoetic Stem Cell Transplantation: Presentation on Behalf of the Astic Trialists. Gastroenterology, 2015, 148, S-163.	0.6	0
574	Preface. Digestive Diseases, 2016, 34, I-I.	0.8	0
575	Large-Scale Integrative Analysis of Epigenetic Modifications Induced by Isotretinoin, Doxycycline and Metronidazole in Murine Colonic Intestinal Epithelial Cells. Epigenomes, 2017, 1, 24.	0.8	0
576	Recurrent Fever and Failure to Thrive in an 11-Year-Old Boy. Case Reports in Gastroenterology, 2019, 13, 350-356.	0.3	0

#	Article	IF	CITATIONS
577	Hypoxia Reduces the Transcription of Fibrotic Markers in the Intestinal Mucosa. Inflammatory Intestinal Diseases, 2021, 6, 87-100.	0.8	0
578	Multi-site therapeutic modalities for inflammatory bowel diseases — mechanisms of action. , 2003, , 523-551.		0
579	NOD2/CARD15 Mutations Associate with Transplant Related Mortality and GvHD in HLA-Identical Sibling Transplants: Detailed Analysis of Single SNPs in 211 Recipient/Donor Pairs Blood, 2004, 104, 424-424.	0.6	0
580	Polymorphisms Within Epithelial Receptors. Methods in Molecular Medicine, 2007, 134, 115-121.	0.8	0
581	Interleukin 10 blocked endoplasmic reticulum stress in intestinal epithelial cells: impact on chronic inflammation. FASEB Journal, 2007, 21, A589.	0.2	0
582	Serological Markers in Inflammatory Bowel Disease. , 2011, , 9-20.		0
583	The Defect in HDL3 Mediated Efflux of Newly Synthesized Cholesterol is Associated with Impaired Activation of Protein Kinase C in Tangier Fibroblasts. , 1995, , 79-87.		0
584	Klassifikationen, Indizes, Aktivitäsbeurteilung. , 2020, , 117-136.		0
585	Klinik der Colitis ulcerosa und Pouchitis. , 2020, , 87-94.		Ο
586	OMO-3â€Safety analysis of filgotinib for ulcerative colitis: Phase 2b/3 selection study and long-term extension results. , 2021, , .		0
587	Genotype-phenotype associations of polymorphisms within the gene locus of NOD-like receptor pyrin domain containing 3 in Swiss inflammatory bowel disease patients. BMC Gastroenterology, 2021, 21, 310.	0.8	0
588	No Need to Scope? Monitoring of Treatment Response in IBD Patients by Transabdominal Ultrasound. Journal of Crohn's and Colitis, 2021, , .	0.6	0
589	Endothelial Barrier Disruption by Lipid Emulsions Containing a High Amount of N3 Fatty Acids (Omegaven) but Not N6 Fatty Acids (Intralipid). Cells, 2022, 11, 2202.	1.8	0